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With a 5-year survival rate of less than 8% pancreatic cancer is one of the most 
aggressive and lethal malignancies. The dismal survival rates in pancreatic 
cancer patients are mainly due to aggressive tumor growth, high metastatic and 
relapse rates as well as resistance to conventional drug therapies. Despite 
research effort in optimizing the therapy, the prognosis remains poor. 
Accordingly, there is a desperate need to develop better treatment strategies to 
optimize therapy of pancreatic cancer patients. Pancreatic cancer exhibits a high 
degree of tumor heterogeneity. Thus, research focuses on the identification of 
various molecular subtypes in PDAC patients based on differential gene 
expression profiles. However, the identified molecular subtypes remain to be 
translated into new therapeutic strategies. The most promising approach is based 
on vulnerabilities caused by variant mutations of DNA damage repair pathways.   
In this study we aimed to determine a deeper mechanistic understanding of 
GSK3β and its influence on pancreatic cancer behavior. Specifically, we 
examined the effect of GSK3β on transcriptional regulation and function of 
pancreatic cancer cells.   
Our study uncovers a previously uncharacterized role of GSK3β in regulating the 
transcription of DNA damage-related genes. Based on our results, we suggest 
that pharmacological targeting of GSK3β may represent a novel and effective 
strategy in the treatment of pancreatic cancer, especially in patients with induced 
DNA damage by variant agents. We show, that irrespective of germline or 
somatic mutations in BRCA genes, there is also the possibility to induce a 
BRCAness subtype at the transcriptional level through inactivation of GSK3β. 
The inhibition of GSK3β in pancreatic cancer cells can therefore cause an 
“inducible” BRCAness-like phenotype.  
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As a direct consequence a higher sensitivity towards various DNA damage-
related agents, e.g. the PARP inhibitor Olaparib, cisplatin and irinotecan, is 
achieved. Furthermore, we unraveled the mechanistic link between GSK3β 
inhibition and “BRCAness” induction and identified NFATc1 as a key 
transcriptional driver of this central pathway in DNA damage regulation. This is in 
line with our observation, that NFTAc1 loss recapitulates the same phenotype as 
GSK3β inhibition. 





1.1. Pancreatic Cancer 
 
With a 5-year survival rate of less than 8% pancreatic cancer is one of the most 
aggressive and lethal malignancies. It is projected to be the second leading cause 
of cancer-related deaths in the upcoming years.1 The dismal survival rates in 
pancreatic cancer patients are mainly due to its aggressive tumor growth with 
early metastasis, the high relapse rate and the remarkable resistance to 
conventional drug therapies. The majority of pancreatic cancer cases are 
diagnosed at late tumor stages, often due to the late onset of clinical symptoms. 
Thus, only few patients are eligible for resection, which is the only curative 
treatment option so far.2,3 Accordingly, there is a desperate need to develop 
better and more effective therapeutic strategies in the treatment of pancreatic 
cancer patients. At the histological level, around 90% of all cases are classified 
as Pancreatic Ductal Adeno Carcinoma (PDAC), originating from the exocrine 
part of the pancreas. PDAC development is preceded by well-defined pre-
malignant lesion, called Pancreatic Intraepithelial Neoplasms (PanIN), and is 
most frequently associated with mutational activation of the KRAS oncogene 
(Kirsten RAt Sarcoma virus). 4–7 In fact, mutations of KRAS are found in early 
PanIN lesions and in approximately 90-95% of all patients with pancreatic 
cancer.8,9 Mutations of Tumor Protein P53 (TP53) and Deleted in Pancreatic 
Cancer-4 (SMAD4) are also signature mutations of pancreatic cancer and are 
found in about 50-60% of all pancreatic cancer patients.7,10 Importantly, about 10-
15% of all pancreatic cancer patients show a familiar background with mutations 
related to DNA damage repair pathways, such as BReast CAncer 1 and 2 
(BRCA1/BRCA2), Partner And Localizer of BRCA2 (PALB2) or Ataxia 
Telangiectasia Mutated (ATM).11–13 Other risk factors of pancreatic cancer 
development include smoking, obesity, and the presence of chronic 
pancreatitis.14 Recently, numerous genome wide genetic and transcriptional 
analysis not only reaffirmed the signature mutations KRAS, TP53 and SMAD4 
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but also demonstrated a high degree of molecular heterogeneity in pancreatic 
cancer. Importantly, these recent studies also showed that pancreatic cancer can 
be classified into distinct subtypes based on their molecular profiles.  These 
current findings open up a new and very attractive field in pancreatic cancer 
research, which aims at a better understanding of the subtypes in tumor biology 
and should reveal new therapeutic strategies.15–17 
 
1.1.1. PDAC Subtypes 
 
Recent transcriptional profiling uncovered the presence of distinct molecular 
subtypes in pancreatic cancer patients.18 The foundation of this exciting new field 
was laid in 2011 by Collisson et al.19, who defined three different subtypes based 
on gene expression analysis in microdissected PDAC tissue. Based on the 
identified gene signatures, subtypes were classified as quasi-mesenchymal 
(QM), classical (CL) and exocrine-like PDAC. Among the three subtypes, quasi-
mesenchymal tumors reflected a particularly aggressive phenotype with the 
lowest survival of all patients.19 Consistently, Moffitt and colleagues20 defined the 
classical and basal-like subtypes with the latter showing poor survival rates.20 In 
a similar study Bailey et al.21  identified four subtypes, which were classified as 
squamous, immunogenic, pancreatic progenitor and Aberrantly Differentiated 
Endocrine eXocrine (ADEX).21 Importantly, further studies (Puleo et al.22) 
described a significant transcriptional overlap between the basal-like phenotype 
and the quasi-mesenchymal and squamous subtype, respectively.22 Taken 
together, there is strong evidence for different molecularly defined tumor 
subtypes in pancreatic cancer. In addition, recent evidence strongly supports the 
idea of subtype-specific tumor biology and phenotypic behavior in pancreatic 
cancer. Accordingly, recent evidence from metabolic profiling studies supported 
subtype-specific differences and emphasized a close association between the 
squamous subtype and a glycolytic profile, while the classical phenotype 
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displayed a lipogenic cell metabolism. Furthermore, it has been shown that 
pancreatic cancer exerts subtype-specific responses to drugs targeting metabolic 
features.23 For instance, a recent study showed a strong impact of Glycogen 
Synthase Kinase 3β (GSK3β) on glycolysis in the squamous subtype.24  This 
finding is of particular interest, as recent studies have shown that GSK3β is often 
induced in PDAC with mutant Ras signaling activation, where the kinase in turn 
activates NF-κB signaling25, or drives glycolysis24 to promote tumorigenesis. 
Moreover, several of those pathways  have been reported by Bailey et al.21 to be 
deregulated  pathways in PDAC (Fig. 1). These interesting findings highly 
suggest a critical role of this kinase in Kras driven carcinogenesis of the pancreas, 







Figure 1: Major pathways altered in pancreatic cancer. Pie graph 
displaying the majorly deregulated pathways in pancreatic cancer with their 
most important key players. The blue color indicates pathways which are 
affected by GSK3β. Modified from Bailey et al. (2016). 
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1.2. Glycogen Synthase Kinase 3β (GSK3β) 
 
1.2.1. Function and regulation 
 
In general, Glycogen Synthase Kinase 3β (GSK3β) is a ubiquitously expressed 
serine/threonine kinase. Two isoforms, termed GSK3α and GSK3β are known so 
far which are encoded by different genes.27 Although the isoforms share a highly 
conserved catalytic domain they target different sets of cell proteins for 
posttranslational modification.28 GSK3 was first discovered as a kinase for 
glycogen synthase, hence its name.29,30 GSK3β is constitutively active in the cell 
and its targets are mostly pre-phosphorylated proteins (primed).31–33 Its activity is 
inhibited by several cellular signaling networks and kinases, including p70 S6, 
p90Rsk, protein kinase A, protein kinase B (AKT) and Protein Kinase C (PKC), 
through phosphorylation at serine 9 (Fig. 2).34 Importantly, these kinases 
themselves are often regulated by more than one signaling cascade (e.g. the 
Mitogen-Activated Protein Kinase (MAPK) pathway, Wnt signaling, mammalian 
Target Of Rapamycin Complex 1 (mTORC1) and PhosphatIdylinositol 3-Kinase 
(PI3K)). The remarkable number of kinases with inhibitory functions on GSK3β 
emphasize the complexity of GSK3β regulation in a cell.35–44 In fact, GSK3β 
activity is tightly controlled by these kinases through a complex network of extra- 
and intracellular signals, including insulin, growth factors, cytokines and 
chemokines as well as Wnt signaling and inducers of apoptosis.44–47  The back 
reaction is induced by protein phosphatase 1 and protein phosphatase 2A. These 
enzymes remove the inhibitory phosphorylation in order to restore the function of 
GSK3β.48–50 Phosphorylation can also cause an enhanced GSK3β function, 
when occurring at tyrosine 216 via autophosphorylation or other kinases.51–53 
Furthermore, the localization of GSK3β determines its downstream factors and 
the complex formation and thus its effects.54,55 The targets of GSK3β are 
numerous and can variably lead to stabilization, inactivation or priming for their 
degradation.52,56 For example phosphorylation of β-catenin, a part of Wnt-
signaling, leads to its degradation.57 Other targets include Nuclear Factor of 
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Activated T cells (NFAT), c-Jun, c-myc and cyclin D1. Their phosphorylation leads 
to nuclear export and subsequent their degradation.58–63 GSK3β-mediated 
phosphorylation of Tau  results in decreased microtubule stabilization. 49,52,64 As 
several target proteins of GSK3β are also known to be deregulated in different 
diseases, GSK3β is often a major player in disease related pathways, either as a 








Figure 2: Regulation of GSK3β activity. GSK3β is constitutively active 
and can be enhanced in its activity by phosphorylation at tyrosine 216
(Tyr216). It has major affinity to primed (already phosphorylated) 
substrates, which are located 4 residues beside the phosphorylation 
side for GSK3β. Its function can be inhibited via phosphorylation at 
serine 9 (Ser9). 
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1.2.2. GSK3β in disease 
 
1.2.2.1. GSK3β in cancer 
 
GSK3β plays a key role in several diseases like neurological and metabolic 
disorders, inflammatory or cardiovascular diseases as well as cancer.33 In 
neurological diseases, namely Alzheimer’s disease, GSK3β affects the 
destabilization of tau, the formation of β-Amyloid plaques as well as the 
impairment of synaptic plasticity and memory formation.65 GSK3β regulates 
important inflammatory transcription factors as Nuclear Factor κ-light-chain-
enhancer of activated B cells (NF-κB), Signal Transducer and Activator of 
Transcription (STAT) or NFAT by controlling the transcription of cytokines and 
the T-cell response. 33,66–68   
GSK3β has a rather ambiguous role in cancer as it can act as a tumor suppressor 
or tumor promoter depending on the tumor identity. GSK3β leads to the 
destabilization of proteins with  important oncogenic functions, like c-Myc, c-Jun 
or β-catenin, thereby playing a tumor suppressive role in various malignant 
contexts.69,70 Its tumor suppressive role was described in skin cancer and 
mammary carcinoma where it suppresses the Wnt/β-catenin pathway and 
decelerates cell cycle progression. It has been shown that during disease 
progression, GSK3β is usually transcriptionally downregulated or inhibited via 
serine 9 phosphorylation.49,71–74 In other contexts like triple negative breast 
cancer, GSK3β promotes tumor growth and drives the acquisition of cancer 
stemness and therapy resistance. Moreover it mediates therapy resistance in 
several tumor entities such as glioma, colorectal and lung cancer as well as 
pancreatic cancer. 75,76 In pancreatic cancer it has been shown that nuclear 
accumulation of GSK3β is associated with a higher grade of dedifferentiation 
displayed as an enhanced  tumor aggressiveness.77 This tumor promoting 
function of nuclear GSK3β was also observed in glioblastoma, where it promotes 
stemness through stabilization of the histone demethylase KDM1A.78 Related 
studies  demonstrated that the combination of GSK3β inhibition with 
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chemotherapeutic agents decreased tumor cell survival.79,80 Another important 
chemo-sensitization mechanism of GSK3β inhibition is induction of DNA damage, 
which has been shown in ovarian cancer, glioblastoma and pancreatic cancer.75 
In ovarian cancer, GSK3β inhibition has been found to destabilize Uracil N-
Glycosylase (UNG2), a protein needed for the initiation of Base Excision Repair 
(BER), causing sensitization to 5-fluorouracil.81 Another DNA repair mechanism 
which is influenced by GSK3β, is DNA double strand break repair via 
phosphorylation of p53-Binding Protein 1 (53BP1) in glioblastoma.82 In pancreatic 
cancer, GSK3β stabilizes DNA TOPoisomerase 2-Binding Protein 1 (TOPBP1), 
a protein involved in the Ataxia Telangiectasia and Rad3-related protein (ATR) 
signaling response upon DNA damage. Thus, the inhibition of GSK3β sensitizes 
cells to the DNA damaging gemcitabine treatment.83 Other oncogenic properties 
contributing to resistance including Epithelial-Mesenchymal Transition (EMT), 
cancer stemness and migration can also be diminished by GSK3β inhibition.76 
Other effects of GSK3β inhibition are the induction of NF-κB-mediated apoptosis 
25,84, causing transcriptional regulation of cell cycle proteins and the induction of 
caspase activity in several cancer identies.85–87 GSK3β also afflicts cell 
proliferation in pancreatic cancer by the stabilization of NFATc2.59,60 NFATc2 
belongs to the family of NFAT proteins which has been shown to be an important 
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1.3. Nuclear Factor of Activated T Cells (NFAT) 
 
Nuclear Factor of Activated T Cells (NFAT) is a ubiquitously expressed group of 
transcription factors, which are involved in several cellular functions such as 
immune response and ER stress. It also plays a major role in human 
malignancies, as it affects processes as proliferation or tumor 
microenvironment.90,91 NFAT proteins comprise four major members, namely 
NFATC1, NFATC2, NFATC3 and NFATC4 .92 The location of NFAT (cytoplasm 
or nucleus) is dependent on its phosphorylation status (Fig. 3).93 When inactive, 
NFAT is hyperphosphorylated and present in the cytoplasm. Upon cell activation 
and increased Ca2+ influx, calmodulin activates the phosphatase calcineurin, 
which in turn dephosphorylates NFAT and thus promots its transition into the 
nucleus.94 Following inactivation via rephosphorylation, NFAT is shuttled to the 
Figure 3: Regulation of NFAT signaling. NFAT is activated through calcium signaling, 
as the Ca2+ causes the activation of calcineurin by calmodulin. Calcineurin causes the 
dephosphorylation of NFAT. NFAT can shuttle in the nucleus afterwords and interact 
with different transcription factors (TF) and depending on those induce gene expression. 
A phosphorylation in the nucleus by GSK3, CK1 or DYRK cause a translocation back 
into the cytosol.  
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cytosol. Several NFAT targeting kinases have been described like GSK3, Casein 
Kinase 1 (CK1) and Dual-specificity Tyrosine-phosphorylation-Regulated Kinase 
(DYRK).95 An interaction of NFAT proteins with other transcription factors and 
chromatin regulatory proteins, like Activator Protein 1 (AP-1), GATA, forkhead 
box P-family proteins or SOX2, is very prominent in the nucleus. These 
interactions determine substrate specificity and regulate gene transcription. 
Another aspect of NFAT regulated signatures is the high dependence on the cell 
type and the nuclear composition of these interacting partner proteins.94,96 Beside 
its role in regulating the innate immune response and inflammation, NFAT can 
regulate apoptosis or cell cycle propagation. Thereby, isoform and cell type 
dependent NFAT can regulate genes that induce or repress cell cycle progression 
as p21, p15, cyclins or cyclin dependent kinases.97 Another aspect is the 
regulation of the transcription of pro- as well as anti-apoptotic genes by NFAT 
isoforms.97 Taking the various mechanisms involving NFAT into account, it is only 
evident that numerous diseases and processes have been shown to be affected 
by NFAT, importantly also cancer.92,98  
 
1.3.1. NFAT in cancer 
 
The deregulation of NFAT plays a major role in oncogenic processes such as 
carcinogenesis, proliferation, metastasis and chemoresistance. These effects  
depend on specific isoforms expression, activation status and interaction 
partners.91,92,95 NFAT is overexpressed or strongly activated in several cancer 
types. Prominent examples are lymphoma, breast or pancreatic cancer. In breast 
cancer NFAT promotes cancer cell invasion via CycloOXygenase 2 (COX2)99,100, 
while in pancreatic cancer NFAT proteins foster tumor growth and survival at least 
in part by inducing c-Myc expression. This process is further facilitated due the 
recruitment of the histone acetylase p300 leading to enhanced binding of ETS 
domain-containing protein Elk1. In addition, silencing of NFAT dramatically 
reduces tumor growth in vivo and in vitro.101,102 Moreover, c-Jun was identified as 
an interaction partner of NFAT involved in acinar cell dedifferentiation.103 The 
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NFATc1/STAT3 complex has been found to be crucial for driving pancreatic 
carcinogenesis.104 In addition to interacting partners, factors regulating NFAT can 
strongly modulate its functions. For example, GSK3β stabilizes NFATc2 in 
pancreatic cancer cells by protecting it from proteasomal degradation.60,105 
Despite its prominent role in PDAC, targeting of NFAT remains challenging, due 
to the broad effects caused to its general inhibition.91,106 
 
1.4. Therapy of PDAC  
 
Despite tremendous effort in defining molecular subtypes in pancreatic cancer 
and translating the results to therapy strategies, molecular-based new therapy 
approaches remain to be developed.  The current standard care for pancreatic 
cancer was slightly improved by introducing new chemotherapeutic regimens 
next to gemcitabine.107 Combining gemcitabine with nab-paclitaxel increases the 
median survival for nearly two months up to 8.5 comparing to gemcitabine 
monotherapy.108 Further improvement in survival was accomplished by 
introducing FOLFIRINOX treatment, which enhanced the survival from 6.8 
months of gemcitabine treated patients up to 11.1 months. FOLFRINOX consists 
of four different chemotherapeutics, namely oxaliplatin, irinotecan, fluorouracil, 
and leucovorin. The treatment is limited to patients with a good performance 
status, due to major side effects.109  Even though these extensions of 
chemotherapeutic treatment improved survival, their minimal effects could be 
caused by disregarding the tumor heterogeneity in pancreatic cancer. The only 
clinically established subclassification that had beneficial effects on treatment, is 
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1.5. DNA Damage Repair  
 
DNA damage repair mechanisms are an important response to prevent genomic 
instability and apoptosis. Subsequently, different repair mechanisms are present 
in the cell to repair damage. DNA Damage Response (DDR) includes detection 
followed by response and repair to maintain the integrity of the genome.111 DNA 
damage can be caused by endogenous events occurring in a regular manner in 
the cell during replication, hydrolytic reactions or by reactive oxygen species112,113 
Exogenous stimuli like toxins, irradiation, or UV light can induce DNA damage as 
well.114  
 
1.5.1. Types of DNA damage and repair 
 
The mechanisms of DNA damage repair are highly dependent on the type of DNA 
damage. Various chemotherapeutic agents act via induction of DNA damage 
resulting in cell death. The standard chemotherapeutic agent gemcitabine, which 
is incorporated in the DNA, evokes the termination of replication.115 This leads to 
stalled replication forks and single strand breaks of the DNA, causing 
apoptosis.116 Another nucleoside analog in PDAC therapy is fluorouracil (5-FU), 
which is an analog of uracil and has a similar mode of action as gemcitabine.117 
The folinic acid leucovorin enhances the effects of 5-FU by inhibiting the 
thymidylate synthase.118 Another component of FOLFIRINOX is irinotecan, which 
is an inhibitor of topoisomerase 1. Topoisomerase 1 is required for relaxing the 
DNA during DNA replication and transcription. Therefore, its inhibition leads to 
the formation of DNA double-strand breaks.119,120 The fourth component of 
FOLFIRINOX is oxaliplatin, which induces stress on ribosome biogenesis.121 
Another treatment option is cisplatin. It displays a high affinity to DNA and binds 
to the nucleophilic N7-sites of purine bases. This process causes intra- and inter-
strand crosslinks.122,123 Repair mechanisms for these crosslinks are nucleotide-
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excision repair and homologous recombination as well as mismatch repair and 
non-homologous end joining .123,124  
 
1.5.1.1. Repair of DNA strand breaks 
 
Two major repair mechanisms for DNA strand breaks are Homologous 
Recombination (HR) and Non-Homologous End Joining (NHEJ). NHEJ can be 
performed during every point of the cell cycle and is not restricted to the S and 
G2 phase, which applies for HR.125  
During NHEJ (Fig. 4) the ends of the DSB are bound by a heterodimer of KU70 
and KU80, which form a complex at the DNA ends. This is followed by binding of 
the DNA-dependent Protein Kinase catalytic subunit (DNA-PKcs), leading to its 
activation via autophosphorylation and the recruitment of Artemis. Artemis is a 
nuclease that prepares the DNA ends for adding nucleotides and ligation of 
strands. This process is affected by the compatibility of the DNA strand ends and 
their modification. Multiple Polymerases (Pol) can implement nucleotides e.g. Pol 
µ or Pol λ. Subsequently, the ends are ligated by the DNA ligase IV. While this 
process does not require a template and is fast, it is very error prone. 
Inappropriate repair can lead to genomic instability resulting in apoptosis and cell 
death.125–128   
A more accurate way to repair DSBs is HR (Fig. 4), which requires a template 
from the sister chromatid.129 The general mechanism involves the initial binding 
of the MRN complex, consisting of MRE11, RAD50 and NBS1 (Nibirn), to the 
DSB ends. Its binding causes the induction of cell cycle regulation, as G2/M arrest 
via ATM signaling, as well as the phosphorylation of histone 2AX and altering of 
the chromatin. A central protein in HR is BRCA1, which is interacting with the 
MRN complex and a plethora of other factors, reflecting its importance in efficient 
HR repair. The CtBP (C-terminal Binding Protein) Interacting Protein (CtIP) then 
binds to the MRN complex. This supports the resection at DSBs as 
endonuclease, as well as it is involved in the recruitment of other DNA repair 
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factors, which also contributes to the resection process.130–132 The binding of the 
Replication Protein A (RPA) to the arisen single-stranded DNA (ssDNA) is the 
first step of the resection process. RAD51 promoted by BRCA2 then replaces 
RPA. This interaction is crucial to promote the strand exchange. The formed 
nucleoprotein filament is crucial for the recognition of the homologic region on the 
template. With the help of cofactors it promotes the strand invasion to the 
template and forming the Displacement loop (D-loop).111,125,133–135 Some major 
proteins being involved in HR disturb the repair network and make a cell 
susceptible for agents requiring HR for damage clearance, as it is shown for 
BRCAness.136 
 





1.5.2. BRCAness  
 
BRCA mutations are well known for increasing the risk of developing various 
malignancies like breast, ovarian, colon, and pancreatic cancer. Due to a recent 
study by Golan et al. (2019)110, Poly [ADP-ribose] polymerase (PARP) inhibitors 
were introduced into clinical guidelines in the United States137.  
Figure 4: DNA double strand repair by the major pathways NHEJ and HR. Simplified scheme of 
the DSB repair pathways. During NHEJ the heterodimers of KU70 and KU80 are binding, which leads 
to binding of DNA-PKcs and recruitment of Artemis, preparing DNA strands for ligation.  Polymerases 
like Pol µ or Pol λ can add nucleotide, followed by the ligation of DNA strand ends via the complex 
of the DNA ligase IV (LIG4), XRCC4 and XLF. The process is error prone, thus it can come to 
insertion of extra nucleotides or deletion. HR is using a template of a sister chromatid to avoid 
mistakes during repair. During the initial step, the MRN complex, CtIP and BRCA1 are binding and 
process the resection of the DNA strand. RPA is binding to the ssDNA, which is replaced by RAD51 
promoted by BRCA2. The nucleoprotein filament is recognizing the homologic region, promotes the 
invasion and formation of the d-loop. It comes to the formation of a Holliday junction and copying and 
repair of the DNA strand break. 
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This was the result of patients with a BRCA mutated tumor showing better 
survival rates, when treated with the PARP inhibitor Olaparib. PARP is an 
important protein involved in the repair of single strand breaks. The inhibition of 
PARP therefore increases double strand breaks formation. Cell death will result 
from accumulating DNA damage, when double strand breaks were not repaired 
by homologous recombination.138  “BRCAness” can also be mediated by mutation 
defects in HR genes other than BRCAs. This is an important factor in mediating 
the same treatment vulnerabilities.138 In PDAC about 24% of patients have a 




1.6. Aim of the project 
 
Recent studies propose an oncogenic function of GSK3β in pancreatic cancer, 
although the underlying mechanisms remain to be determined. It also remains 
unclear whether and how GSK3β targeting offers a promising strategy in 
pancreatic cancer treatment. In this study we aimed to determine a deeper 
mechanistic understanding of its role in the regulation of pancreatic cancer 
behavior. Specifically, we examined the effect of GSK3β on transcriptional 
regulation and function of pancreatic cancer cells. The comprehension of 
important transcription factors being involved in the effects of GSK3β is a 
promising approach in improving stratification of patients, who might benefit from 
a combination therapy of chemotherapeutics with GSK3β inhibitors.  Thus, the 
key novelty of this work is to evaluate the potential of GSK3β-related treatments 
in combination with other therapeutics to improve therapy outcome, based on a 
prior stratification.   
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2.1.1. Buffers  
 
Table 1. Composition of buffers and solutions. 
Buffer/Solution Composition 
Blocking solution 5 % (w/v) milk powder in TBS-T  
BSA blocking solution 5 % (w/v) BSA in TBS-T 
Buffer A 10 mM Hepes pH 7.9, 10 mM KCl, 0,1 mM 
EDTA, 0,1 mM EGTA, 0.1 M DTT, 1x 
cOmpelte   
Buffer C  20 mM Hepes pH 7.9, 0.4 M NaCl, 1 mM 
EDTA, 1 mM EGTA, 0.1 M DTT, 1x 
cOmpelte   
Citrate buffer 10 mM citric acid monohydrate, pH 6.0 
Crystal violet solution 0.1 % (w/v) crystal violett, 20 % (v/v) EtOH 
in H2O 
Gomes lysis buffer 150 mM NaCl, 1 % (v/v) NP-40, 0.5 % (w/v) 
sodium deoxycholate, 50 mM Tris-HCl 
(pH 8.0), 20 mM EDTA, 20 mM NaF 
Gomes wash buffer 100 mM Tris-HCl (pH 8.5), 500 mM LiCl, 
1 % (v/v) NP-40, 1 % (w/v) sodium 
deoxycholate, 20 mM EDTA, 20 mM NaF  
5x Laemmli buffer 225 mM Tris pH 6.8, 50 % (v/v) glycerol, 
5 % (w/v) SDS, 100 mM DTT, 0,02 % (w/v) 








150 mM NaCl, 20 mM EDTA (pH 8.0), 
50 mM Tris (pH 7.5), 0.5 % (v/v) NP-40, 1 % 
(v/v) Triton X-100, 20 mM NaF 
PB 17 mM monobasic sodium phosphate, 
60 mM dibasic sodium phosphate, adjust to 
pH 7.4 
PBS 137 mM NaCl, 2.7 mM KCl, 1.8 mM 
KH2PO4,10 mM Na2HPO4, adjust to pH 7.2-
7.4 
PBS-T buffer PBS, 0.01 % (v/v) Triton X-100  
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Running buffer 25 mM Tris, 190 mM glycine, 0.1 % (w/v) 
SDS 
SDS separating gel (x %): x % (v/v) Acrylamide, 375 mM Tris (pH 8.8), 
0.1 % (w/v) SDS, 0.1 % (w/v) APS, 0.04 % 
(v/v) TEMED 
SDS stacking gel 5 % (v/v) acrylamide, 125.5 mM Tris 
(pH 6.8), 0.1 % (w/v) SDS, 0.1 % (w/v) APS, 
0.1 % (v/v) TEMED 
TBE buffer 0.13 M Tris, 45 mM boric acid, 2.5 mM 
EDTA 
TBS-T buffer 0.2 M Tris base, 1.5 M NaCl, 0.05 % (v/v) 
Tween 20 
TE buffer 10 mM Tris-HCl (pH 8.0), 1 mM EDTA 
(pH 8.0) 
Weinmann buffer 50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 
1 % (v/v) SDS 
Whole cell lysis buffer 50 mM HEPES pH 7.5-7.9, 150 mM NaCl, 
1 mM EGTA, 10 % (v/v) Glycerin, 1 % (v/v) 
Triton X-100, 100 mM NaF,10 mM Na4P2O7 
x 10 H2O, 1x cOmpelte   
 
 
2.1.2. Chemicals and reagents 
 
Table 2. Chemicals and reagents. 
Chemicals/Reagents Company 
2-mercaptoethanol Carl Roth, Karlsruhe, Germany 
Aceton AppliChem GmbH, Darmstadt, Germany 
Acrylamide Carl Roth, Karlsruhe, Germany 
Agarose  Nippon Genetics, Tokyo, Japan 
Agarose A/G Beads   Merck, Darmstadt, Germany 
Ampicilin Merck, Darmstadt, Germany 
AMPure XP beads Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
APS Carl Roth, Karlsruhe, Germany 
ATP Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Boric acid Merck, Darmstadt, Germany 
Bromophenol blue Merck, Darmstadt, Germany 
BSA Merck, Darmstadt, Germany 
Buffer O Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
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Chloroform AppliChem GmbH, Darmstadt, Germany 
Citrtic acid Carl Roth, Karlsruhe, Germany 
Competent E. coli 10beta  New England Biolab, Ipswich, USA 
cOmplete Roche, Rotkreuz, Switzerland 
Crystal violet Carl Roth, Karlsruhe, Germany 
DAPI Merck, Darmstadt, Germany 
DMEM, Gibco Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
DMSO Merck, Darmstadt, Germany 
DNA Marker Plus 1kb Nippon Genetics, Tokyo, Japan 
DTT Merck, Darmstadt, Germany 
EDTA Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
EGTA Merck, Darmstadt, Germany 
Ethanol Carl Roth, Karlsruhe, Germany 
Fast Digest BBsI Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
FBS BIOWEST SAS, Nuaillé, France 
Formaldehyde Merck, Darmstadt, Germany 
Glycerol Merck, Darmstadt, Germany 
Glycine Carl Roth, Karlsruhe, Germany 
H2O2 AppliChem GmbH, Darmstadt, Germany 
HCl AppliChem GmbH, Darmstadt, Germany 
Heamatoxilin  Merck, Darmstadt, Germany 
HEPES Carl Roth, Karlsruhe, Germany 
High range protein ladder Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Hoechst Merck, Darmstadt, Germany 
ImmoMount Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Isopropanol AppliChem GmbH, Darmstadt, Germany 
KCl Merck, Darmstadt, Germany 
LB Agarose Merck, Darmstadt, Germany 
LB Media Merck, Darmstadt, Germany 
LiCl Merck, Darmstadt, Germany 
Linear acrylamide BIORON, Römerberg, Germany 
Lipofectamin 2000 Bio-Rad, Hercules, USA 
Mastermix for Syber Green Bio-Rad, Hercules, USA 
MEM NEAA (100x), Gibco Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
MEM, Gibco Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Methanol Carl Roth, Karlsruhe, Germany 
Midori Green Nippon Genetics, Tokyo, Japan 
Milk powder Carl Roth, Karlsruhe, Germany 





Merck, Darmstadt, Germany 
MTT Biomol, Hamburg, Germany 
NaCl Merck, Darmstadt, Germany 
NaF Merck, Darmstadt, Germany 
Nitrocellulose membrane Bio-Rad, Hercules, USA 
Normal Goat Serum Abcam 
NP-40 Merck, Darmstadt, Germany 
Page Ruler™ prestained 
ladder (26616) 
Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Pen/Strep, Gibco® Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
PFA  AppliChem GmbH, Darmstadt, Germany 
Phenol/Chloroform/Isoamyl 
alcohol 
Carl Roth, Karlsruhe, Germany 
Primer/sgRNA Merck, Darmstadt, Germany 
Protein assay dye reagent 
concentrate 
Bio-Rad, Hercules, USA 
Proteinase K AppliChem GmbH, Darmstadt, Germany 
RNaseA Merck, Darmstadt, Germany 
Roti Mount Carl Roth, Karlsruhe, Germany 
ROTIclear Carl Roth, Karlsruhe, Germany 
RPMI, Gibco Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
SDS Carl Roth, Karlsruhe, Germany 
siLentFect Bio-Rad, Hercules, USA 
SOC outgrowth media New England Biolab, Ipswich, USA 
Sodium deoxycholate Merck, Darmstadt, Germany 
sodium phosphate dibasic Carl Roth, Karlsruhe, Germany 
Spectra Mulitcolor High 
Range Protein Ladder 
(26625) 
Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
 
Super Script II Reverse 
Transcriptase 
Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
T4 Ligase Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Tango Buffer Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
TEMED Carl Roth, Karlsruhe, Germany 
Trans-Blot Turbo RTA 
Transfer Kit 
Bio-Rad, Hercules, USA 
Tris AppliChem GmbH, Darmstadt, Germany 
Tris-HCl Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
TRIzol Reagent Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
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Trypsin 10x, Gibco Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Tween-20 Merck, Darmstadt, Germany 
Western Lightening Plus 
ECL 
Perkin-Elmar, Waltham, USA 
Western Lightening Ultra Perkin-Elmar, Waltham, USA 
Xylol AppliChem GmbH, Darmstadt, Germany 
 
 
2.1.3. Equipment and consumables 
 
Table 3. Equipment and consumables. 
Equipment/Consumables Company 
Ariumpro ultrapure water 
system 
Sartorius, Göttingen, Germany 
Benchtop Automated 
Tissue Processor 
Leica Biosystems, Wetzlar, Germany 
Biorupter Pico Diagenode, Denville, USA 
Cell Culture 6-well plate Sarstedt, Nümbrecht, Germany 
Cell Culture 96-well plates Greiner Bio One, Kremsmünster, Austria 
Cell Culture Flask Sarstedt, Nümbrecht, Germany 
Cell Scraper Sarstedt, Nümbrecht, Germany 
Cell strainer, 50 µM  BD Bioscience, Franklin Lakes, USA 
ChemoStar ECL Imager INTAS Science Imaging Instruments, 
Göttingen, Germany 
Combitips advanced Eppendorf, Hamburg, Germany 
Combitips advanced, 
Biopur 
Eppendorf, Hamburg, Germany 
Cryopure vial Sarstedt, Nümbrecht, Germany 
FACS CantoII BD Bioscience, Franklin Lakes, USA 
Falcon Tube 15 mL/ 50 mL Sarstedt, Nümbrecht, Germany 
Fluorescence Microscope 
System for Advanced 
Imaging Widefield 
Systems 
Leica Camera, Wetzlar, Germany 
HERAcell 240i CO2 
incubator 
Thermo Fischer Scientific, Waltham, USA 
HistoCore Arcadia C 
cooling plate 
Leica Biosystems, Wetzlar, Germany 
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IKAMAG Magnetic Stirrer 
RCT 
IKA, Staufen, Germany 
Light microscope "BX43" Olympus, Tokyo, Japan 
Light microscope "BX43" Olympus, Tokio, Japan 
Low binding micro tubes Sarstedt, Nümbrecht, Germany 
Mettler Toledo FE20 
FiveEasy Benchtop pH 
meter 
Thermo Fischer Scientific, Waltham, USA 
MicroAmp Fast Optical 96-
Well Reaction Plate 
Thermo Fischer Scientific, Waltham, USA 
MicroAmp Optical 
Adhesive Films 
Thermo Fischer Scientific, Waltham, USA 
Micropipette tips TipOne Starlab, Hamburg, Germany 
Microplate reader 
"PHOMO" 
Autobio, Zhengzhou, China 
Microscope – BX43F/ 
CKX53 
Olympus Corporation, Tokyo, Japan 
Microtome (Leica 
RM2265) 
Leica Biosystems, Wetzlar, Germany 
Mini-PROTEAN Tetra 
handcast system 




Bio-Rad Laboratories, Hercules, USA 
Multifuge X1 Centrifuge 
Series 
Thermo Fisher Scientific, Waltham, USA 
Multipette plus Eppendorf, Hamburg, Germany 
NanoPhotometer P-330 INTAS Science Imaging Instruments, 
Göttingen, Germany 
Neubauer chamber Assistant, Sondheim/Rhön, Germany 
Nitrocellulose membrane Bio-Rad Laboratories, Hercules, USA 
Paraffin Tissue embedder 
(EG1150H)  




Peqlab, Erlangen, Germany 
Pipetboy acu 2 INTEGRA Biosciences, Biebertal, Germany 
Pipetboy acu 2  INTEGRA Biosciences, Biebertal, Germany 
Pipettes, Research Plus Eppendorff, Hamburg, Germany 
Polystyrene Tube with 
Screw Cap 
Greiner Bio One, Kremsmünster, Austria 
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PowerPac Basic Power 
Supply 
Bio-Rad Laboratories, Hercules, USA 
Precision balance PCB Kern & Sohn, Balingen, Germany 
PSU-20i Orbital Shaking 
Platform 
Grant Instruments, Shepreth, UK 
Qubit Fluorometer 3 Thermo Fisher Scientific, Waltham, USA 
Reactions Cups 0.5 mL, 
1.5 mL, 2 mL 
Sarstedt, Nümbrecht, Germany 
Safe 2020 Class II 
Biological Safety Cabinets 
Thermo Fischer Scientific, Waltham, USA 
Scotsman AF80 Ice Flaker Hubbard Systems, Suffolk, UK 
Serological pipettes Sarstedt, Nümbrecht, Germany 
Shadon Sequenza System Thermo Fisher Scientific, Waltham, USA 




Thermo Fisher Scientific, Waltham, USA 
Superfrost glass slides Thermo Fischer Scientific, Waltham, USA 
ThermoMixer Eppendorf, Hamburg, Germany 
TipOne filtertips Starlab, Hamburg, Germany 
Trans-Blot Turbo Transfer 
System 
Bio-Rad Laboratories, Hercules, USA 
VacuuHandControl VHCpro Vacuubrand, Wertheim, Germany 
Vacuum pump: BVC 
Control 
Vacuubrand, Wertheim, Germany 
Water bath (WNB14) Memmert, Schwabach, Germany 














Table 4. Kits. 
Kit Company 
Cell Proliferation ELISA, 
BrdU, colorimetric 
(11647229001)  
Merck, Darmstadt, Germany 
Bioanalyzer High 
Sensitivity DNA Analysis 
(5067-4626) 
Agilent, Santa Clara, USA 
DAB ImmPACT Vector Laboratories, Burlingame, USA 
iscript cDNA Synthesis Kit Bio-Rad, Hercules, USA 
iscript Universal SYBR 
Green Supermix 
Bio-Rad, Hercules, USA 
Macherey-Nagel 
NucleoBond Xtra 




Lonza Group, Basel, Switzerland 
Peroxidase Rabbit IgG 
Vectastain ABC Kit 
Vector Laboratories, Burlingame, USA 
Peroxidase Mouse IgG 
Vectastain ABC Kit 
Vector Laboratories, Burlingame, USA 
Qubit dsDNA HS Assaykit Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
DNeasy Blood & Tissue 
Kit 
Qiagen, Venlo, Neatherlands 
Trans-Blot Turbo RTA 
Midi Nitrocellulose 
Transfer Kit 
Bio-Rad, Hercules, USA 
TruSeq RNA Library Prep 
Kit v2 Set A,B 
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2.1.5. Therapeutic drugs 
 
Table 5. Therapeutic drugs. 
Drug Company 
9-Ing-41 Aobious, Gloucester, MA, USA 
AR-A014418 Abmole Bioscience Inc., Houston, USA 
Cisplatin Merck, Darmstadt, Germany 
Olaparib Selleckchem, Houston, USA 





Table 6. Software. 
Software Version Company 
ChemoStar  0.3.28.0 Intas Science Imaging Instruments, 
Göttingen, Germany 
DESeq2 1.22.1 140 
FASTQC 0.65 141 
FASTQ Trimmer 1.0.0 142 
GraphPad Prism 7.05 GraphPad, San Diego, USA 
htseq-count 0.6.1p1 143 
Image Lab 5.2.1 Bio-Rad, Hercules, USA 
Inkscape   1.0  
PVC Viewer 1.5.3.1 Implen, München, Germany 
SortSam 2.18.2.1 144 
TopHat v2.1.1 145 
CellSens Entry 1.12 Olympus Corporation, Tokyo, Japan 












2.2.1. Cell culture 
 
For in vitro studies, established human and murine pancreatic cancer cell lines 
as well as primary murine pancreatic cancer cells isolated from the KPC (K-
rasLSL.G12D/+; Trp53R172H/+; Pdx-1-Cre) model146 and the KNPC (K-rasLSL.G12D/+; 
NFATc1 c.a.; Trp53R172H/+; P48-Cre/+)96 model were used. Further, cell lines 
isolated from patient derived xenografts (PDX) and provided by CP1 of the 
Clinical Research Unit 5002 were analyzed. In brief, PDX derived cell lines (CDX) 
were isolated from patient tumor material which have been cultivated for several 
generations in mice. CDX indicated with “Bo” as well as PDX material, were kindly 
provided by the collaboration with Prof. S. Hahn (Ruhr-Universität Bochum) and 
Prof. J. Siveke (University Hospital Essen). Chemotherapeutic agents and 
inhibitors used in this study are displayed in table 5. The inhibitors were solved in 
DMSO. Control conditions were treated with the same solvent content as 
treatment samples. 
Table 7. Media compositions of cell lines. 
Cell line Origin Media composition 
KPCbl6 murine DMEM, 10 % (v/v) FCS, 1 % (v/v) 
NEAA 
KPCbl6 – ctr Klone murine DMEM, 10 % (v/v) FCS, 1 % (v/v) 
NEAA 
KPCbl6 – NFATc1 k.o. 
#1 
murine DMEM, 10 % (v/v) FCS, 1 % (v/v) 
NEAA 
KPCbl6 – NFATc1 k.o. 
#2 
murine DMEM, 10 % (v/v) FCS, 1 % (v/v) 
NEAA 
KPCbl6 – NFATc1 k.o. 
#3 
murine DMEM, 10 % (v/v) FCS, 1 % (v/v) 
NEAA 
KNPC murine DMEM, 10 % (v/v) FCS, 1 % (v/v) 
NEAA 
L3.6  human MEM, 10 % (v/v) FCS 
Capan1 human RPMI, 10 % (v/v) FCS 
Capan2 human RPMI, 10 % (v/v) FCS 
CDX-5 human RPMI, 10 % (v/v) FCS 
CDX-7 human RPMI, 10 % (v/v) FCS 
CDX-62-Bo human RPMI, 10 % (v/v) FCS 
 Materials and Methods  
28 
 
   
CDX-80-Bo human RPMI, 10 % (v/v) FCS 
CDX-85-Bo human RPMI, 10 % (v/v) FCS 
CDX-57-Bo human RPMI, 10 % (v/v) FCS 
CDX-13 human RPMI, 10 % (v/v) FCS 




2.2.2. CRISPR/Cas9-mediated knockout 
 
To generate knock-out cells for NFATc1 in KPCbl6 cells, we used the 
CRISPR/Cas9 system. The protocol was kindly provided by Feda Hamdan. 
Single guide RNAs (sgRNA) targeting exon 3 kindly provided and designed by 
Marie Hasselluhn (AG Hessmann) were used. Oligomers were annealed, by 
mixing 20 µL of the upper and lower oligo [100 µM] with 10 µL of Buffer O and 50 
µL of H2O. The mix was incubated for 10 min at 95 °C in a water bath (600 mL), 
followed by cooling down in the water bath (transfer to 4 °C) for two hours. The 
product was diluted 1:400 for subsequent cloning into the PX-458 vector.   The 
vector includes a Cas9 endonuclease, a green fluorescent protein (GFP)-tag for 
sorting purposes and an ampicillin resistance for selection. For ligation the 
reaction mix (100 ng PX-458 plasmid, 2 µL annealed oligos, 2 µL Tango Buffer, 
1 µL DTT (10 mM), 1 µL ATP (10mM), 1 µL Fast Digest BBsI, 0.5 µL T4 Ligase, 
filled up with H2O for a final volume of 20 µL) was incubated in a thermocycler for 
six cycles (each 5 min at 37 °C followed by 5 min at 21 °C).  For the transformation 
into Escherichia coli (E. coli), competent cells were incubated with 2 µL of the 
ligation product for 35 s at 42 °C, followed by 5 min on ice. The cells were then 
mixed with 400 µL of SOC media, incubated for 1 h at 37 °C. Afterwards, bacteria 
were plated onto Ampicillin (50 µg/mL)-containing LB agarose plates. Single 
colonies were picked, cultivated/cultured and subsequently plasmids isolated. 
The successful implementation of the oligos was confirmed by sequencing 
(Microsynth Seqlab, Göttingen). For the transfection, 5 µg of the plasmid were 
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mixed with 1 mL of OptiMEM and 25 µL of Lipofectamin 2000, followed by an 
incubation for 10 min at room temperature (RT). Cells were supplemented with 
fresh media before adding the transfection reagents mix. For the generation of 
single cell clones, cells were trypsinized after 48 h, washed with PBS and 
resuspended in PBS prior to cell sorting. Additionally, cells were filtered (50 µm 
cell strainer) to remove non single cells beforehand. Sorting and separation of 
successfully transfected cells (GFP-positive) was performed by the central 
service unit for cell sorting of the UMG (S. Becker, Department of Hematology 
and Oncology, University Medical Center Göttingen). To avoid cell lines 
originating from multiple clones, wells were observed in a regularly manner and 
wells containing more than one primary colony were excluded. Confirmation of 
NFATc1 knockout was performed by PCR, Western blot and qRT-PCR. RNA and 
proteins were isolated as described in 1.2.7. and 1.2.9. DNA was isolated 
following the instructions of the DNeasy Blood & Tissue Kit. After a positive result 
by PCR, indicated by a change of the fragment size, clones were sequenced 
(Microsynth Seqlab, Göttingen) to confirm the knockout of NFATc1 in KPCbl6 
cells.  
 
Table 8. Oligonucleotides for generation of NFATc1 knockout cells in murine KPCbl6 cells. 
Target Sequence 
NFATc1 Exon3 5'GACCGGCTGTAGCTCGGCACTGCAG 
NFATc1 Exon3 5'AAACCTGCAGTGCCGAGCTACAGCC 
 
 
2.2.3. Polymerase chain reaction (PCR)   
To validate the NFATc1 knockout in KPCbl6 cells, isolated genomic DNA (gDNA) 
was used for the PCR, using primers flanking the putative region in which the 
sequence had been edited. The PCR reaction mix (2.5 µL 10x buffer, 1.25 µL 
Primer rev/for, 0.5 µL JumpStart Polymerase, 0.5 µL dNTPs, 100 ng DNA, final 
volume 25 µL) was run on a thermocycler. The settings are shown in table 9. The 
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PCR product was supplemented with 6x loading dye and loaded on a 1 % 
agarose gel supplemented with Midori Green (in TBE buffer). Bands were 
visualized using the Gel Doc.  
 
Table 9. PCR program for CRISPR/Cas9 validation. 
Temp. [°C] Time [min]  
95 3  







72 10  
 
Table 10. Primer to validate CRISPR/Cas9 mediated NFATc1 knock-out. 
Target  Sequence 
Primer 1 forward 5'ATCTGCCTGTCTGTCTGTGC 
 reverse 5'TCATAACCCGCTCCCTCAGA 
Primer 2 forward 5'TGCTGGGTAGATGCAGACAC 
 reverse 5'AGCCATTCCCTCTGTGAGGA 
 
 
2.2.4. Transfection of cells 
 
2.2.4.1. siRNA-mediated knock-down 
For a temporary knock-down, cells were seeded in a 6-well plate. The media was 
removed after 24 h and 1.5 mL of fresh growth media were added. For one 
reaction, 500 µL of Opti-MEM were mixed with 6 µL siRNA  and 6 µL of 
siLentFect. The mix was incubated for 20 min at RT and then supplemented to 
the normal growth media. Depending on the experiment, cells were harvested 
after 24-72 h.  
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GSK3β murine 185671 
 
Thermo Fisher Scientific, 
Waltham, Massachusetts, 
USA 
GSK3β human S6240 Thermo Fisher Scientific, 
Waltham, Massachusetts, 
USA 
NFATc1 murine 288360 
 










2.2.4.2. Plasmid transfection 
 
For the transfection of plasmids, cells were seeded in a 6-well plate and cultured 
until the required confluency was reached. Before the transfection, media was 
removed, and 1.5 mL of normal growth media added. For the reaction, 1 µg of 
the needed plasmid and Lipofectamine2000 (2.5 µL for 1 µg of DNA) were added 
to 500 µL of Opti-MEM. The mix was incubated for 10 min at RT prior transfection. 
As control, an empty vector was transfected. Cells were harvested as indicated 
in the corresponding experiment.  
 
Table 12. Plasmids. 





Kindly provided by Steven Johnsen 
GSK3β wt-HA tag pcDNA3, Amp was a gift from Jim Woodgett 
(Addgene plasmid # 14753)147 
Vector control pCMV2C Stratagene 
NFATc1 c.a.- HA 
tag 
MSCV, Amp was a gift from Neil A. Clipstone  
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2.2.5. Flow cytometry 
Cell cycle analysis   
Cells were cultivated and treated as indicated in the corresponding experiment. 
After the treatment, cells were trypsinized, counted and up to 1,000,000 cells 
transferred into a (15 mL/50 mL) falcon. For fixation, cells were centrifuged at 
1200 rpm for 3 min (RT) and the pellet resuspended in 600 µL PBS. While 
vortexing the sample, 1.4 mL of ice-cold ethanol (100 %) was added dropwise. 
Samples were incubated for 30 min at 4 °C, followed by a centrifugation (1,200 
rpm, 3 min, RT). The supernatant was discarded and the pellet washed two times 
with 1 mL of washing solution (PBS + RNase A (5 µg/mL)). After the last 
centrifugation and discarding the washing solution, cells were resuspended in 
100 µL of PBS supplemented with 5 µL Hoechst. The sample was incubated for 
30 min at 37 °C, followed by measurement (FACS CantoII, BD Biosciences), 
wherefore it was diluted with 400 µL of PBS. Analysis was performed using 
FlowJo.  
 
2.2.6. Functional assays 
MTT assay   
Cells were seeded depending on their proliferation rate and the treatment 
duration in a corresponding density. The control cells were seeded so that they 
did not reach 100 % confluency at the endpoint of treatment. For a treatment of 
72 h, 1,200 KPCbl6 cells, 2,000 L3.6 cells and 5,000-8,000 cells of CDX cells 
were seeded as quintuplicates in a 96-well plate. Cell viability and metabolic 
activity were measured by adding thiazolyl blue tetrazolium bromide (MTT, 5 
mg/mL in H2O) for a final concentration of 0.5 mg/mL to the culturing media of the 
cells and incubated for 2 h. CDX were incubated for 4 h. After incubation, media 
was removed and cells were dissolved in solubilization solution for 20 min at RT. 
The amount of metabolized MTT was measured at 595 nm using a photometer.  
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BrdU assay   
For evaluation of the proliferation rate, cells were seeded in 96-well plates as 
indicated for the MTT assay and incubated as required for the corresponding 
experiments. For the BrdU assay, the manufacturer's protocol of the Colorimetric 
cell proliferation ELISA kit was followed. Treatments were performed in technical 
and biological triplicates.  
 
Crystal violet assay  
For the crystal violet staining, cells were seeded in 24-well or 96-well plates and 
incubated as shown in the corresponding experiments. At the endpoint, cells were 
fixed by adding 4 % PFA in PBS for 10 min. After incubation, PFA was removed 
and cells were incubated for 10 min covered in crystal violet solution (0.1 % (w/v) 
crystal violet, 20 % (v/v) EtOH in H2O). After the removal of the solution, cells 
were washed with H2O to remove unbound crystal violet. Staining was 
documented by pictures and quantified by dissolving in MTT solubilization 
solution and measurement at 595 nm with a photometer. 
 
2.2.7. Extraction of RNA 
For RNA extraction from cell culture experiments, cells were washed twice with 
PBS. Subsequently, cells were dissolved in TRIzol (0.5 mL/ well/ 6-well plate). 
Chloroform (200 µL per 500 µL of TRIzol) was added, samples vortexed and 
centrifuged (13,000 rpm, 30 min, 4 °C). The aqueous phase was collected and 
an equal amount of isopropanol added. Samples were mixed and incubated at -
80 °C for 1 h. Sample were centrifuged for 30 min at 13,000 rpm, 4 °C and the 
supernatant removed. The pellet was washed twice with 500 µL of 70 % (v/v) 
EtOH. After EtOH removal, the pellet was dried, resuspended in nuclease-free 
water and stored at -80 °C. The quality of RNA was controlled by measuring the 
photometric values.   
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2.2.8. Quantitative real time polymerase chain reaction  
(qRT-PCR) 
The cDNA synthesis for the qRT-PCR was carried out by using 1 µg of RNA and 
following the manufacturer’s instructions of the BioRad cDNA synthesis kit. The 
final product was diluted 1:5 in nuclease-free H2O. Samples were run in technical 
and biological triplicates. For relative Ct values, values were normalized to Ct 
values of RPLP0. For running qRT-PCR, the iTaq Universal SYBR Green 
Supermix was utilized. One reaction was composed of 3.9 µL H2O, 0.05 µL of 
each primer (10 pmol), 5 µl iTaq Universal SYBR Green Supermix and 1 µL of 
the template cDNA. Primers are listed in table 13. The qRT-PCR program 
specifications are shown in table 14. qRT-PCR was performed using the software 
StepOne v2.3.  
 
Table 13. Human primer sequences for qRT-PCR. 
Target  Sequence 
BRCA1 forward 5' GCCTTCTAACAGCTACCCTTC 
 reverse 5' CTTCTGGATTCTGGCTTATAGGG 
BRCA2 forward 5'TGCTGGGTAGATGCAGACAC 
 reverse 5'AGCCATTCCCTCTGTGAGGA 
ATM forward 5’ATTCCGACTTTGTTCCCTCTG 
 reverser 5’CATCTTGGTCCCCATTCTAGC 
ATR forward 5’GAAAGAGGCTCCTACCAACG 
 reverse 5’CATTTCTAGTCGAGCTACCCAG 
RPLP0 forward 5’TGGGCAAGAACACCATGATG 
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Table 14. Program for qRT-PCR. 
Temp. [°C] Time 
[min] 
 
95 10:00  
95 0:15 40 cycles (qRT-PCR) 
60 1:00 50 cycles (ChIP-qRT-PCR) 
Melt Curve 





Table 15. Primer for ChIP-qRT-PCR. 
Target    Sequence 
BRCA2  forward  5' GCCAGTCGACCTCCTTCAC 
  reverse  5' AGCCGAGACACACACGTTAG 
BRCA1  forward  5'CCAGACAGCATGGAACCACA 
  reverse  5'ACTGAGAAACAGAACAAAGCGG 
 
 
2.2.9. Protein extraction  
 
Isolation of whole cell lysate (WCL)   
For extraction of whole cell lysate, cells were washed twice with ice-cold PBS, 
followed by lysis in WCL buffer. Subsequently, cells were scraped in lysis buffer 
and collected. After an incubation of 30 min on ice, samples were centrifuged at 
full speed for 20 min. The supernatant was used for Western blot analysis.  
The protein concentration was measured using the Bio-Rad Protein Assay, 
following the manufacturer’s manual. Samples and standard were measured in 
duplicates on a microtiter plate. As standard increasing concentrations of bovine 
serum albumin (BSA) solved in WCL buffer were used. To measure the 
absorbance at 595 nm using a photometer, 200 µL of the Bio-Rad Protein Assay 
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Reagent were mixed with 1 µL of the sample or the different standard solutions. 
Based on the standard curve, the concentration of the sample was calculated.  
 
2.2.10. Western blot 
For Western blot analysis, 20-30 µg protein in Laemmli Buffer [1x] were heated 
up to 95 °C for 5 min and loaded on a sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). For size indication, corresponding protein ladders 
were applied. After separation, proteins were transferred via the Trans-Blot Turbo 
Transfer system onto a nitrocellulose membrane for 15 to 35 min. After the 
transfer, membranes were blocked in blocking solution or BSA blocking solution 
(table 1) for 1 h at RT. The primary antibody was incubated over night at 4 °C in 
5 % (w/v) milk/BSA in TBS-T. After washing the membrane in TBS-T (3x 10 min), 
the membrane was incubated with a secondary antibody (coupled with 
horseradish peroxidase (HRP)) diluted in 5 % milk (w/v) in TBS-T for 1 h at RT. 
After incubation, the membrane was washed again in TBS-T (3x 10 min), followed 
by detection via Chemocam Imager, using Western Lightening ECL/Ultra 
reagent.  
 
Table 16. Antibody dilutions for Western blot. 











A3854 Merck, Darmstadt, Germany 
GSK3β rabbit 1:1,000/ 
milk 
9315 Cell Signaling Technology, 
Inc., Danvers, United States 
NFATc1 mouse 1:500/ 
BSA 
sc-7294 Santa Cruz Biotechnology, 
Dallas, United States 
γH2AX mouse 1:1,000/ 
BSA 
80312 Cell Signaling Technology, 
Inc., Danvers, United States 
HA rabbit 1:1,000/ 
milk 
3724 Cell Signaling Technology, 
Inc., Danvers, United States 









7074 Cell Signaling Technology, 







7076 Cell Signaling Technology, 
Inc., Danvers, United 
States 
 
2.2.11. Immunofluorescence (IF) 
Immunofluorescent stainings were performed on KPCbl6 cells seeded on 
coverslips. Cells were seeded, allowed to grow for 24 h, followed by treatment 
with cisplatin. After treatment, cells were fixed with 4 % PFA in PB for 10 min. 
After fixation, PFA was removed and cells washed twice with PB. Cells were 
permeabilized using 0.4 % Triton-X100 in PB for 10 min. Prior to the primary 
antibody, cells were blocked with 5 % normal goat serum (NGS) in PB for 1 h at 
RT. The primary antibody was incubated in 5 % NGS in PB (concentration 
indicated in table 17) over night at 4 °C. Cells were washed three  times for 10 
min with PB and incubated for 1 h with the secondary antibody (diluted in 5 % 
NGS in PB) at RT, washed again for three times, incubated for 3 min with DAPI 
(0.2 mg/mL), followed by three times washing. Cells were mounted on glass 
slides using Immomount.  
 
Table 17: Antibody dilutions used for IF. 






Donkey 1:500 A10042 Thermo Fisher Scientific, 
Waltham, USA 
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2.2.12. Immunohistochemistry (IHC) 
Tumor tissue of cisplatin-treated C57BL6 mice orthotopically transplanted with 
KPCbl6 cells was kindly provided by the group of Prof. Dr. Matthias Dobbelstein 
within the cooperation of KFO 5002. Furthermore, patient biopsies were a kind 
gift of Prof. Dr. Phillip Ströbel and the Department of Pathology. The TMA staining 
of NFATc1 were performed and graded by Nai-Ming Chen (AG Ellenrieder). The 
GSK3β TMA staining was kindly stained by the Department of Pathology by 
Hanibal Bohnenberger and graded by Nai-Ming Chen. 
 
Tissue preparation   
In brief, tissue was fixed in 4 % PFA (in PBS) at RT overnight followed by the 
dehydration in EtOH using a tissue processor. The tissue was transferred 
stepwise to increasing EtOH concentrations (55 %, 85 %, 96 %, 100 %, 100 %, 
100 %, 1 h incubation each). Finally, the tissue was transferred to xylol three 
times (1 h each) and finally transferred to paraffin until embedding. Cooled blocks 
(4 °C, overnight) were cut in sections of 4 µm using a microtome. Sections were 
dried at 37 °C overnight.    
 
Staining    
The tissue sections were deparaffinized twice for 10 min in Roticlear, followed by 
rehydration in decreasing EtOH concentrations, (99 %, 99 %, 96 %, 80 %, 70 % 
and 50 %, 3 min incubation each). After three washes  in tab water, slides were 
boiled in citrate buffer for 20 min and allowed to cool down for 30 min on ice. 
Followed by washing three times in tab water, slides were incubated in 3 % of 
H2O2 (in deionized H2O) for 10 min. For blocking and antibody incubation, slides 
were fixed in the Shadon Sequenza system. After washing with PBS containing 
either 0.1 % (v/v) Tween-20 or Triton X-100 (PBS-T), non-specific antigens were 
blocked with 10 % (w/v) BSA in PBS-T for 1 h at RT. Antibody dilutions are 
indicated in table 17. The primary antibody was diluted in PBS-T containing 1 % 
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(w/v) BSA and incubated over night at 4 °C. Unbound antibody was removed by 
washing three times with PBS-T. The slides were incubated for 1 h with the 
corresponding biotinylated secondary antibody (Vectastain ABC kit). The 
secondary antibody was diluted 1:200 in PBS-T containing 1 % (w/v) BSA. After 
incubation, slides were washed three times with PBS-T and then incubated for 1 
h with the AB-mix that was prepared half an hour before usage. For one slide, 1 
µL of solution A and 1 µL of solution B were mixed with 200 µL of PBS-T. 
Subsequently, the slides were washed three times with PBS-T. The DAB 
Substrate Kit was used for signal detection after manufacturer’s protocol. The 
reaction was stopped by transferring the slides into tab water. Afterwards, slides 
were stained for 3 min in hematoxylin and washed for 5 min in tab water. Before 
mounting, sections were dehydrated by increasing EtOH concentrations (70 %, 
80 %, 96 %, 99 %, 2 min incubation each), followed by incubation in Roticlear 
(four times, 10 min each). Finally, sections were mounted with Rotimount and 
coverslips.  
 
Table 18. Antibody dilutions for IHC. 





GSK3β rabbit 1:400/ 
Triton 
12456 Cell Signaling 
Technology, Inc., 
Danvers, United States 
γH2AX mouse 1:100/ 
Triton 
80312 Cell Signaling 
Technology, Inc., 
Danvers, United States 
 
 
2.2.13. Chromatin immunoprecipitation (ChIP) 
 
The ChIP protocol was adapted from Najafova et al.148. Cells were fixed with 1 % 
formaldehyde (in PBS) at RT for 20 min and quenched by adding glycerol (final 
concentration of 125 mM) for 5 min at RT. Plates were washed twice with ice-
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cold PBS and 1.5 mL (for a 15 cm plate) of nuclear preparation buffer (containing 
1x cOmplete). Cells were scraped, collected and centrifuged (2 min, 12,000 g, 4 
°C). The nuclear pellet was washed with 1 mL of nuclear preparation buffer and 
centrifuged again. The remaining pellet was resuspended in 200-600 µL of 
Gomes Lysis Buffer (with 0.1 % (v/v) SDS) and incubated on a rotating wheel for 
15 min at 4 °C. Samples were split in 200 µL fractions and sonicated for 20-30 
cycles (30 s On/Off) with the Bioruptor Pico. Samples were pooled, centrifuged 
(10 min, 12,000 g, 4 °C) and the supernatant was collected. From each sample, 
10 µL were used for the shearing check. Therefore, 1 µL Proteinase K (20mg/mL) 
and 0.3 µL of RNase (30 µg/µL) were added to the sample and incubated for 3 h 
at 55 °C and overnight at 65 °C. DNA fragments supplemented with 6x DNA 
loading dye were separated on a 1.5 % agarose gel (supplemented with Midori 
green). If the fragments had reached the required size, it was proceeded with the 
samples or samples sonicated a second time. Therefore, samples were diluted 
up to 500 µL with Gomes Lysis buffer (containing 1x cOmplete) and 100 µL of 
sepharose beads (50 % slurry in Gomes Lysis Buffer) were added and incubated 
(1 h, 4 °C, on a rotating wheel). After centrifugation (2 min, 12,000 g, 4°C), the 
supernatant was collected. The precleared sample was split for the different IPs, 
IgG control and input (control?). The aliquots were filled up with Gomes Lysis 
buffer (containing protease inhibitors) to a final volume of 500 µL and incubated 
with the antibody (1-2 µg/IP) overnight at 4 °C while rotating. The input was frozen 
until further processing. Sepharose beads were blocked with 1 mg/mL BSA in 
Gomes Lysis Buffer at 4 °C while rotating overnight. Beads were washed three 
times with Gomes Lysis Buffer and centrifuged for 2 min at 1,000 g. After the final 
removal of the lysis buffer, lysis buffer was added in a 1:1 ratio to the beads for a 
50 % slurry. To each IP,30 µL of blocked beads were added and incubated for 2 
h (rotating, 4 °C). The complexes were washed once with Gomes Lysis Buffer (1 
mL), twice with Gomes Wash, once again with Gomes Lysis Buffer and twice with 
TE buffer. For isolation of the DNA, 50 µL Tris (10 mM, pH 8.0) with RNase (0.2 
µL) were added to the samples and incubated for 30 min at 55 °C. Then, 50 µL 
2x Weinmann Buffer and 1 µL Proteinase K (20 mg/mL) were added and the 
samples incubated overnight at 65 °C. The samples were centrifuged (2,000 g, 2 
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min) and the supernatant was collected. 100 µL Tris (10 mM, pH 8.0) were added 
to the beads, incubated (10 min, 65 °C, 800 rpm) and centrifuged (5,000 g, 2 
min). The supernatant was added to the first fraction and supplemented with 10 
µL LiCl (8 M), 4 µL linear acrylamide and 200 µL phenol/chloroform/isoamyl mix 
(25:24:1), vortexed for 30 s and centrifuged for 2 min at full speed. The aqueous 
phase was collected. To the phenolic phase, 200 µL Tris (10 mM, pH 8.0) and 
0.4 M LiCl were added, vortexed for 30 s and centrifuged for 2 min at full speed. 
The aqueous phase was added to the first fraction. 1 mL 100 % EtOH was added 
and the mixture incubated for at least 2 h at -80 °C. After centrifugation (15,000 
g, 30 min, 4°C), the supernatant was removed, the pellet washed once with 70 % 
EtOH and centrifuged again (15,000 g, 30 min, 4°C). The pellet was allowed to 
dry and finally resuspended in 80 µL nuclease free H2O. The samples were 
further analyzed via qRT-PCR. 
Table 19: Antibody dilutions for ChIP. 
Target Species Dilution  Number Company 








2.2.14. RNA sequencing 
Sequencing of mRNA (non-stranded) was performed in triplicates of L3.6 cells 
with knock-down of GSK3β, control treatment and treatment with the GSK3β 
inhibitor AR-A 014418 (10 µM) for 48 h. RNA was isolated as described in 1.2.7. 
and its quality checked via an RNA gel. Therefore, samples were loaded on a 1 
% agarose gel (containing Midori Green Advance) to determine RNA integrity. 
Bands were visualized using the GelDoc. Library preparation was performed by 
using the TruSeq RNA Library Prep Kits and following the manufacturer's 
protocol. The final product concentration was measured via Qubit. Further, the 
fragment sizes and purity were analyzed by using the Agilent Bioanalyzer 2100 
(high sensitivity DNA analysis kit, Agilent 5067-4626). Samples were pooled in 
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an equal ratio and sequenced by the NGS Integrative Genomics Core Unit, 
University Medical Center Göttingen, Germany.  
Sequencing data analysis   
The provided FastQ files were analyzed on usegalaxy.org149. For quality control, 
the FASTQC (version 0.65)141 was used. The sequences were trimmed by 11 
bases at the 5’ end using the FASTQ trimmer (version 1.0.0)142. TopHat tool 
(version 2.1.1)145 was employed for mapping to the human transcriptome (hg19) 
under very sensitive bowtie2 settings, followed by SortSAM (version 2.18.2.1)150.  
Read counts were obtained by HTSeq (version 0.6.1p1; -f bam -r pos -s reverse 
-a 10 -t exon -m union)143. Differential gene expression was analyzed via DESeq2 
(version 2.11.40.6)140. For subsequent pathway analysis, genes with log2fold 
values ≥ 0.5 and ≤ -0.5, padjusted ≤ 0.05, were used. Differential gene set 
analysis was performed using GSEA (version 4.0.3)151,152 as well as gene 
ontology analysis (geneontology.org) via Panther overexpression test (version 
15.0, Fisher’s exact test, false discovery rate (FDR)) with GO database or 
Reactome pathway database. Heatmaps of selected genes were generated with 
GraphPad Prim7 using log2fold changes. 
 
2.2.15. Data analysis 
 
Statistical analysis was performed with Graph Pad Prism7 using the unpaired 
student t-test and indicating significances with * p < 0.05, ** p < 0.01, and 
*** p < 0.001. Graphs show the mean of three biological replicates and standard 







































In this study, we investigate the oncogenic role of GSK3β in the context of 
pancreatic cancer. GSK 3β is known to be highly expressed in dedifferentiated 
tumors of PDAC and involved in regulating cell growth and 
chemoresistance.60,77,83,105 However, a deeper understanding of the molecular 
mechanisms underlying these effects is necessary to develop better targeted 
therapies. This study aims to uncover these mechanisms with the overall goal of 
defining subgroups of pancreatic cancer patients that will benefit from therapy 
with GSK3β inhibitors.  
 
3.1. GSK3β is associated with poor survival in PDAC 
patients 
 
GSK3β was reported to either have tumor promoting or suppressive role 
depending on the origin of the tumor and the cellular context.  GSK3β was 
reported to mainly play an oncogenic role in the case of pancreatic cancer.60,77,79 
To validate this, we analyzed the expression and protein levels in three different 
cohorts, composed the publicly available TCGA (Cancer Genome Atlas 
Database) database, a cohort of tissue microarrays, and tumors of patient derived 
xenografts. The TCGA database consists of 172 pancreatic cancer patients from 
which we selected for the survival analysis the 25% percentile with the highest 
and lowest expression values (OncoLnc.org). This revealed that high mRNA 
expression of GSK3β correlates with worse overall survival rates in PDAC 









An independent cohort of 70 PDAC patients was dissected in regard of the tumor 
composition in cooperation with Dr. Hanibal Bohnenberger (Institute of 
Pathology, Göttingen) and Dr. Nai-Ming Chen. Consistently, evaluation of the 
human tissue microarrays (TMA) from the obtained patient samples showed a 
high expression of GSK3β in almost two thirds of the analyzed tumors (Fig. 5B). 
Representative pictures of the TMA display the differences in GSK3β levels (Fig. 
5C). Furthermore, we analyzed the GSK3β expression in a cohort of patient-
derived xenografts (PDX) (n=29). Our findings in PDX tissue were consistent with 
the TMA as we similarly observed high expression of GSK3β in various PDXs 
(Fig. 6A). Moreover, nuclear GSK3β was seen in about 10% of all tumors.  
Figure 5: GSK3β expression correlates with survival in human pancreatic cancer 
samples. A) TCGA analysis by OncoLnc (Anyada et al., 2016) shows a significant correlation 
between the expression of GSK3β and the survival of patients as depicted in the Kaplan Meyer 
plot. The survival of the low and high GSK3β expression, displaying the 25 % of the upper and 
lower percentile of GSK3β expression among the patient cohort.  B) GSK3β staining of TMA 
showing different expression levels in pancreatic cancer patients of the Göttingen cohort. 
Patients were scored into four different groups (0-3) based on their expression. The score 
represents negative staining as 0 and gradually increases to 3 as the highest intensity of 
GSK3β signal. C) Representative pictures of the GSK3β scores, displaying the intensity of 





Score 0 Score 1 Score 3 
p = 0.00501 
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Nuclear localization of GSK3β has been shown to be indicative for a particular 
aggressive phenotype in pancreatic cancer77. In addition, cells isolated from PDX 
tumor tissue (CDX) were tested for their GSK3β expression levels in comparison 
to the well-established murine KPCbl6 cell line. Interestingly, differences 
observed in the PDX tissue can also be displayed by protein levels in the CDX 
(Fig. 6B). Therefore, testing in CDX cell lines provides a platform which enables 
us to test our findings in cell lines derived of tumors, representing different 






Figure 6: GSK3β in patient-derived xenograft (PDX) models. A) PDX tumor sections were 
stained for GSK3β by IHC and subsequent analyzed based on their localization. B) Whole cell 
protein lysates of various CDXs were tested via western-blot to evaluate their GSK3β 
expression levels under normal growth conditions. β-actin served as a loading control.     
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3.2. Inhibition of GSK3β leads to decreased 
proliferation and    induction of cell cycle arrest 
 
Next, we studied the functional consequences of GSK3β inhibition on pancreatic 
cancer cell proliferation and viability. For this purpose, we performed MTT assays 
in human L3.6pl cells and in metastatic KPCbl6 cells, which were derived from 
the KPC (K-rasLSL.G12D/+; Trp53R172H/+; Pdx-1-Cre) mouse model146. L3.6pl is a 
well-established cell line, representing the highly aggressive and chemotherapy 
resistant basal-like phenotype153. Both cell lines were cultured in serum-
containing media and in the presence of increasing doses of AR-A 014418 (AR-
A), a specific GSK3β inhibitor154. We were able to demonstrate a dose-dependent 
decrease in cell viability in both models (Fig. 7). Notably, L3.6pl cells showed a 






Figure 7: GSK3β leads to decreased proliferation and cell viability. MTT assays were 
performed after 72 h of treatment with AR-A and show a dose dependent decrease of cell 
proliferation and cell viability in KPCbl6 (A) and L3.6pl (B), n=3 (biological replicates with 5 
technical replicates); unpaired student t-test of biological replicates; ** p≤ 0.01, *** p≤ 0.001, 
**** p ≤ 0.0001, mean +SD. 
A B 
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To confirm these findings, we extended our proliferation analysis and treated an 
additional set of CDXs with increased concentrations of AR-A. Interestingly, these 
cell lines were derived from PDXs with various localization patterns of GSK3β. 
PDX-13 exhibiting higher nuclear accumulation compared to the cytosolic 
accumulation in PDX-57 (Bo) (Fig. 8A). However, their total GSK3β expression 
levels do not differ on the CDX level. Interestingly, CDX-13 cells, which are 
derived from the PDX-13, were more sensitive to GSK3β inhibition compared to 
CDX-57(Bo) cells (Fig. 8B). This implies that nuclear GSK3β levels can be 




Figure 8: PDX-derived cell lines respond differently to GSK3β inhibition. A) 
Representative pictures of PDX13 and PDX-57 (Bo) that was used to derive cell lines 
(CDX), PDX-13 shows a higher nuclear localization (indicated by arrow) of GSK3β in 
comparison to PDX-57 (Bo). Scale bar indicates 20 µM. B) CDX cells lines were treated 
for 72 h with AR-A and the cell viability measured via MTT assay. CDX.13 showing a higher 
sensitivity towards AR-A treatment. n=3 (biological replicates with n=5 technical 
replicates); unpaired student t-test of biological replicates - comparison of DMSO to single 
treatments for each individual cell line; ** p≤ 0.01, *** p≤ 0.001, mean +SD,  
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Upon validation of the growth limiting effects of GSK3β inhibition, we tested its 
impact on cell cycle transition. Therefore, we performed flow cytometry analysis 
in both cell lines using increasing concentrations of the inhibitor. These studies 
revealed that GSK3 inhibition by AR-A treatment causes a dose-dependent G2/M 















Figure 9: Cell cycle analysis in KPCbl6 and L3.6. Cell cycle analysis via flow 
cytometry in KPCbl6 (A) and L3.6 (B). Cells, treated with increasing concentrations of 
the GSK3β inhibitor AR-A for 24 h, show the induction of G2/M arrest. n=3 (biological 
replicates), mean +SD.  
A B 
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3.3. GSK3β inhibition leads to the induction of DNA 
damage-related gene signatures  
 
To elucidate the molecular mechanisms underlying the oncogenic role of GSK3β 
in pancreatic cancer, we performed gene expression profiling by mRNA 
sequencing in L3.6pl cells which are highly responsive to AR-A treatment. Cells 
were treated with AR-A (10 µM) or DMSO as control and RNA was isolated for 
subsequent transcriptome-wide expression. The treatment duration of 48 hours 
was determined as time-point with minimal cell death while observing stable 
effects on the transcriptional level  to ensure the uncovering of direct effects of 
GSK3β perturbation. 
Differential genes expression analysis via DESeq2140 revealed about 6000 
regulated genes (log2fold change ≤ -0.5, ≥ 0.5; q ≤ 0.05) while 3718 genes being 
downregulated. Principle Component Analysis (PCA) showed clustering within 
the replicates but not between the conditions which supports high homogeneity 
between the replicates (Fig. 10). Additionally, the first principle component 
accounted for 99% the variability between conditions indicating that the 
differences between the treated and untreated cells is due to the treatment and 
not to any other technical factors. Furthermore, Gene Set Enrichment Analysis 
(GSEA) 151,152 (Fig. 11) confirmed downregulation of previously described GSK3β 
target genes, e.g. members of the AKT signaling pathway and genes involved in 
glycolysis. These results are consistent with a recent publication by Brunton et 
al. (2020) reporting GSK3β-mediated regulation of glycolysis, especially in 
squamous subtypes. In addition, our profiling analysis demonstrated a strong 
transcriptional repression of EMT gene signatures, indicating a role of GSK3β in 
Figure 10: Principal component analysis of mRNA-seq in L3.6. PCA plot of 
control group and AR-A treated samples by DESeq2 analysis.  
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transcriptional regulation of cell plasticity and invasion and of cell cycle control 
genes. In addition, we observed the regulation of metabolic processes and 
protein transport via microtubules to be affected (Fig. 12). Thus, supporting 
findings of GSK3β participation in those pathways.33,155 We found differential 
expression of key DNA repair mechanisms, most prominently BRCA1, and 
interestingly also genes involved in cisplatin responses (Fig. 11). To identify 
genes that are transcriptionally dependent on GSK3β, we focused our analysis 
on downregulated genes upon its pharmacological inhibition by AR-A. Gene 
ontology (GO) enrichment analysis of significantly downregulated genes upon 
AR-A treatment confirmed DNA double strand repair and DNA replication gene 
sets (Fig. 12). The revealed pathways in GSEA and GO analysis have in common 
to regulate different DNA damage repair mechanisms as homologous 
recombination, regulating signatures of important proteins of this process as 
BRCA1 or to modulate a general response to DNA damage. Furthermore, we 
observe signatures downregulated under GSK3β that are connected to a 
response to cisplatin. Cisplatin induced DNA damage is repaired by different 
pathways including HR, connecting these findings to the DNA damage repair 
signatures. Taken together, these pathways implicate a role of GSK3β in DNA 
damage repair. 
 












Figure 11: GSEA analysis shows downregulation of DNA repair pathways 
and EMT. Norm-counts of significantly regulated genes (log2fold change ≤ -0.5, 
≥ 0.5; q ≤ 0.05) of DESeq2 analysis were used to perform GSEA analysis, 
showing the regulation of pathways related to EMT, glycolysis, cell cycle 




























Figure 12: GSK3β inhibition leads to downregulation of DNA damage-related gene 
signatures. Gene ontology analysis (geneontology.org) by PANTHER, using significantly 
downregulated genes (log2fold change ≤ -0.5; q ≤ 0.05), showing overrepresented biological 
processes with an FDR ˂ 0.05.  
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3.3.1. Comparative analysis of genes regulated by GSK3β 
inhibition and knockdown 
 
To validate the specificity of the findings under GSK3β inhibition, we next 
performed mRNA-seq of L3.6pl cells upon siRNA-mediated knockdown of 
GSK3β. DESeq2 analysis revealed a clustering of the treatment conditions (Fig. 
13). However, GSK3β inhibition and knockdown conditions show differences in 









Figure 13: PCA blot of RNA-seq in L3.6pl including GSK3β knockdown. PCA plot of the 
control group, AR-A-treated samples and siGSK3β by DESeq2 analysis.  
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Subsequently, we compared up and downregulated by AR-A as well as GSK3β 
knockdown (log2fold change ≤ -0.5, ≥ 0.5; q ≤ 0.05).  The analysis of the 640 
genes which were downregulated under both conditions (Fig. 14A) confirmed the 
transcriptional regulation of DNA damage repair signatures involved in double-
strand break repair or homologous recombination. Based on the results of the 
Gene Ontology and GSEA analysis a collection of genes important in the 
regulation of DNA damage repair and cisplatin response were selected. Those 
are visualized in the heatmap in Fig. 14B. Thus, important genes for DNA damage 
repair are downregulated upon knockdown GSK3β, although not as strong as by 




Figure 14: Downregulated gene signatures by AR-A treatment and siGSK3β. A) Number 
of genes regulated by AR-A treatment or siGSK3β. 650 genes are downregulated by AR-A 
and siGSK3β. Those were utilized for enrichment analysis (Pathway Commons analysis; 
webgestalt.org), showing that the top ten enrichment of pathways are related to DNA damage 
and DNA replication. B) Log2 fold changes of selected genes involved in DNA repair. Those 
genes significantly downregulated under AR-A treatment are marked in bold, displaying a 
difference in strength between inhibition and knockdown. 
Pathway Name Adjusted p-value 
Double-Strand Break Repair 0.0730 
Homologous recombination repair of  
replication-independent double-strand breaks 
0.0852 
Homologous Recombination Repair 0.0852 
Recruitment of repair and signaling  
proteins to double-strand breaks 
0.1022 
serine biosynthesis 0.1022 
BARD1 signaling events 0.1643 
Fanconi anemia pathway 0.2190 
Superpathway of serine and  
glycine biosynthesis I 
0.2591 
NADE modulates death signalling 0.2591 
Unwinding of DNA 0.2591 
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To further validate our findings, we verified the downregulation of crucial genes 
involved in DNA repair using qRT-PCR. Indeed, we were able to verify that genes 
with implications in DNA damage repair were downregulated upon AR-A 
treatment (Fig. 15). Mutational loss or transcriptional silencing of these genes is 
associated with severe defects in HR and DNA repair, increased sensitivity 
towards platinum-based chemotherapy and PARP inhibitors.156 Tumor subtypes 
with defects in homologous recombination are defined as “BRCAness” tumors. 
Of note, BRCAness induced defects in HR mechanisms often compensate for 
repair disturbances through increased non-homologous end joining, resulting in 
higher chances to accumulate aberrations.136  Thus, we hypothesize that the 
inhibition of GSK3β causes an “inducible” BRCAness phenotype that is initiated 





Figure 15: Representative genes related to DNA damage 
repair are downregulated by AR-A. L3.6 cells were treated 
for 48 h with 10 µM AR-A. Expression levels were normalized 
to the housekeeping gene RPLP0 and further normalized to 
the control treatment. Mean +SD, n=3 (biological replicates 
with 3 technical replicates), unpaired student t-test; *** p≤
0.001, **** p ≤ 0.000. 
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3.4. DNA damage is induced by GSK3β inhibition 
 
Based on the results of our mRNA-seq analysis, we aimed to further determine if 
the regulation of genes by GSK3β, involved in homologous recombination and in 
general DNA damage repair, have a biological relevance. Moreover, the strong 
regulation of genes like BRCA1 or BRCA2 suggested that co-treatment (of 
GSK3β inhibitors) and DNA damaging agents (e.g. cisplatin) or PARP inhibitors 
in pancreatic cancer cells157 could be beneficial.  
 
 
To test our hypothesis, we first evaluated the sensitivity of KPCbl6 and L3.6pl 
cells to cisplatin treatment (Fig. 16) and demonstrate only moderate growth 
inhibition upon treatment with 1 µM cisplatin. This concentration was used for 
further studies. Next, we simultaneously treated KPCbl6 and L3.6pl cells with 
cisplatin or AR-A alone, or in combination for 24 h and stained for γH2A.X, a well-
established DNA damage marker158. While single treatment with either cisplatin 
or AR-A alone already induced a moderate γH2A.X increase, the combination of 
both agents resulted in severe DNA damage (Fig. 17). 
Figure 16: Cisplatin treatment in KPCbl6 and L3.6. Cells (KPCbl6 (A), L3.6pl (B)) were 
treated with increasing concentrations if cisplatin (solved in H2O) for 72 h. The cell viability
was evaluated by MTT assay in KPCbl6 and L3.6. Mean +SD, n=3 (biological replicates with 
5 technical replicates), unpaired student t-test, * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p ≤
0.0001. 
A B 





Together, these experiments suggested that inactivation of the GSK3β kinase 
enhances the DNA damage induced by cisplatin in pancreatic cancer cells. In line 
with the enhanced levels of DNA damage we induced an accentuated growth 
reduction via MTT assay caused by the combination of AR-A and cisplatin 



































Figure 18: Simultaneous treatment of AR-A and cisplatin increased DNA damage in 
vitro. KPCbl6 (A) and L3.6 (B) cells were treated with 10µM AR-A, 1µM cisplatin and their
combination for 24 h. After treatment, DNA damage was determined by detecting γH2AX. β-











































Figure 17: KPCbl6 cells show reduced proliferation under 
treatment of AR-A and cisplatin. MTT assay in KPCbl6 cells after 48 
h treatment with 10 µM AR-A, 1µM cisplatin or their combination shows 
a decrease of cell viability when combining the treatments. Mean +SD, 
n=3 (biological replicates with 5 technical replicates), unpaired student
t-test, * p≤ 0.05, ** p≤ 0.01, **** p ≤ 0.0001. 
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3.4.1. DNA damage induction is reproducible upon GSK3β 
knockdown and a different GSK3β inhibitor 
 
To confirm this model, we carried out an additional set of experiments and treated 
pancreatic cancer cells with cisplatin in the presence and absence of endogenous 
GSK3β. For this purpose, we silenced GSK3β in KPCbl6 cells before treatment 
with cisplatin for 24 hours (Fig. 19A).  
 
Importantly, GSK3β silencing caused a moderate induction of DNA damage and 
strongly sensitized pancreatic cancer cells to cisplatin treatment. In fact, we 
observed a significant and robust increase in DNA damage, as indicated by a 
strong increase in γH2A.X staining. These results confirmed our pharmacological 
studies using AR-A and emphasized a critical role of GSK3β inhibition in 
sensitization of cells towards cisplatin. In line with this conclusion, application of 
another GSK3β inhibitor, named 9-ING-41, caused a robust increase in DNA 




























































control cisplatin 1µM  
A B 
Figure 19: DNA damage is increased by co-treatment with 9-ING-41 or GSK3β knockdown. 
A) siRNA mediated knockdown of GSK3β was performed for six hours followed by cotreatment 
with 1 µM cisplatin for 24 h in KPCbl6 cells. B) GSK3β inhibitor 9-ING-41 was combined with 
cisplatin for 24 h in KPCbl6 cells. DNA damage was evaluated by γH2AX levels. β-actin serves 
as loading control.  
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3.4.2. GSK3β inhibition induces sensitivity towards various DNA 
damaging agents 
 
As our hypothesis claims the induction of a BRCAness phenotype through 
GSK3β inhibition, we sought to verify this effect by testing AR-A treatment in 
combination with other chemotherapeutic agents, as well as PARP inhibition. For 
chemotherapy, we decided to treat cells with SN-38, the activated form of 
irinotecan, part of the FOLFIRINOX treatment regime for pancreatic cancer 
patients. For inhibition of PARP, we treated cells with Olaparib. The co-treatment 
of AR-A with SN-38 enhanced the effect of the single drugs on DNA damage 
levels (Fig. 20A). Also, the combination of AR-A with Olaparib had a beneficial 

























































 A B 
Figure 20: GSK3β inhibition sensitized cells towards treatment with PARP inhibitors 
and SN38. A) L3.6 were treated with SN38, the activated form of irinotecan, and AR-A for 
24 hours. Cells displayed an increase of DNA-damage if cotreated. β-actin serves as 
loading control. B) KPCbl6 cells were treated with Olaparib, a PARP inhibitor, and AR-A 
for 48 hours, followed by evaluation of cell viability by MTT assay, whereby co-treatment 
decreases cell viability. Mean +SD, n=3 (biological replicates with 5 technical replicates), 
unpaired student t-test, * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001. 
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3.4.3. GSK3β inhibition induced DNA damage is dependent on 
the BRCA mutation status 
 
To test, if the effect we observe on DNA damage levels is based on the 
downregulation of BRCA1 and BRCA2, we studied other cell lines than KPCbl6 
and L3.6pl. As both do not contain known BRCA mutations. Therefore, we 
compared CAPAN1 and CAPAN2 cells. CAPAN1 cells comprise a BRCA2 
mutation, leading to a truncated protein and a loss a function.159 This leads for 
CAPAN1 to display higher sensitivity towards cisplatin treatment. On the other 
hand, CAPAN2 cells are devoid of a BRCA mutation. We treated both cell lines 
with AR-A for 48 and 72 hours and compared their DNA damage level. We could 
observe that AR-A does not affect the DNA-damage levels irrespective of the 
duration of the treatment in CAPAN1 (Fig. 21). Conversely, we detected an 
increase of DNA damage under AR-A treatment in CAPAN2 cells further 
supporting our model that pharmacological inhibition of GSK3β leads to 





















































Figure 21: Cell line specific response to GSK3β inhibition. 
CAPAN1 and CAPAN2 cells were treated for 48 and 72 hours with 
AR-A (5 and 10 µM). Only in CAPAN2 does AR-A induce DNA 
damage. β-actin servers as loading control. 
A 
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3.5. GSK3β accumulates in the nucleus upon cisplatin 
treatment 
 
Based on our observation that GSK3β inhibition induces DNA-damage and most 
importantly sensitize the cells to cisplatin treatment, we wanted to test how 
treatment with cisplatin influences GSK3β. Therefore, we decided to test tumor 
sections of mice treated with cisplatin or control treatment. These were kindly 
provided by Katharina Ewers (Institute of Molecular Oncology, University of 
Göttingen). Prior the treatment, mice have been orthotopically transplanted with 
KPCbl6 cells. After the development of tumors, mice were treated for two weeks, 
whereby the group of cisplatin treated mice, received 4 mg/kg two times per 
week. The sections were stained for GSK3β and as treatment control for γH2AX.  
 
 
Interestingly, we were able to observe a stronger nuclear localization of GSK3β 












Figure 22: Cisplatin treatment induced GSK3β expression in vivo. Orthotopically 
transplanted KPCbl6 cells (in C57BL6 mice) were treated for two weeks (two injections
i.p. [4 mg/kg.] /week) with cisplatin. Pictures show representative staining of control and 
treated mice. Arrow indicates nuclear localization of GSK3β and γH2AX in cisplatin 
treated mice. Scale bar indicates 20 µM.  
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Additionally, we performed immunofluorescence staining of GSK3β in KPCbl6 
cells after 24 hours of treatment with 1 µM of cisplatin. The short-term treatment 
induced nuclear localization of GSK3β, associated with a more aggressive 
phenotype77, in comparison with the control cells. (Fig. 23). Thus, confirming the 




Based on the upregulation and most important the nuclear localization of GSK3β 
observed under cisplatin treatment in tumors and KPCbl6 cells, we aimed to test 
how increasing levels of GSK3β influence the response to cisplatin.  
Figure 23: Cisplatin treatment induces nuclear shift of 
GSK3β in vitro. KPCbl6 cells, treated with 1 µM of cisplatin for 
24 h and subsequently stained for GSK3β (red) using 
immunofluorescence. Nucleus was stained with DAPI (blue). 
Representative pictures showing a nuclear shift of GSK3β 
induced by cisplatin. Scale bar indicates 25 µm. 
 Results  
64 
 
For this purpose, we overexpressed GSK3β in KPCbl6 cells, followed by cisplatin 
treatment for 24 hours (Fig. 24). Therefore, we overexpressed a wildtype GSK3β. 
Interestingly, not only did the overexpression of GSK3β already reduce the basal 
level of DNA damage, but it also attenuated cisplatin-induced damage. Based on 
these results, we can conclude that high levels of GSK3β attenuate the DNA 









control cisplatin 1µM 
γH2AX 
β-actin 
Figure 24: GSK3β overexpression leads to 
decreased DNA damage under cisplatin treatment. 
GSK3β construct containing HA-tag were transfected in 
KPCbl6 cells. After 24 h, they were cotreated with 1µM 
of cisplatin for 24 h. Transfection efficiency was 
controlled by HA and DNA damage by γH2AX. β-actin 
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3.6. NFATc1-dependent signatures regulated by GSK3β 
inhibition 
 
Subsequently, we aimed to identify a possible mechanism which leads to the 
effects of GSK3β inhibition on DNA damage repair. When analyzing gene 
signatures regulated by AR-A, we found, beside the already mentioned 
pathways, ATF2 signatures. ATF2 (Activating Transcription Factor 2) is a 
member of the AP-1 protein family.160 Moreover, it has already been shown that 
ATF2 activation is enhanced after cisplatin treatment and regulates signatures 
related to cisplatin and genotoxic stress.161,162 However, when we tested for an 
alteration of ATF2 levels we did not observe differences after treatment with AR-
A. Furthermore, we did not detect a differential interaction of ATF2 with GSK3β 
after cisplatin treatment via Co-Immunoprecipitation. Therefore, we screened for 
other potential interaction partners of GSK3β that might lead to a differential 
transcriptional regulation of DNA damage repair genes. An important interaction 
partner of AP-1 proteins is the family of NFAT proteins.163 As previously 
demonstrated by our group, NFAT is stabilized by and interacts with GSK3β 59 
and, thus, we focused on how NFAT might influence the regulation of DNA 
damage repair.  
Therefore, we compared an NKCII data set of our department (MC Hasselluhn, 
GE Schmidt et al., 2019)88 with the mRNA-seq data of L3.6pl of this study. NKCII 
cells have a constitutively active NFATc1 and a KRAS mutation. Hereby, we 
compared the control group with the knockdown of NFATc1 (siNFATc1).  
With the purpose of finding genes regulated by AR-A treatment as well as by 
NFATc1, we performed a comparison of genes downregulated in both 
experiments (log2 fold change ≤ -0.5, q ˂ 0.05). Thus, we found 262 genes 
downregulated in both treatment groups (Fig. 25). This collection of genes was 
further processed by GO enrichment analysis (PANTHER, Fisher Exact test, FDR 
˂ 0.05). The analysis clearly shows the regulation of DNA damage pathways, 
including DNA damage repair by homologous recombination and repair of DNA 
double strand breaks (Fig. 25).  


















      by AR-A 
Downregulated  
by siNFATc1 
Figure 25: Gene signatures downregulated by AR-A and siNFATc1 are strongly 
involved in DNA repair. Genes identified by mRNA-seq that are significantly 
downregulated by AR-A in L3.6 and siNFATc1 in NKCII cells were compared (log2fold ≤ -
0.5, q ˂ 0.05). The overlap of 262 genes was used for GO Enrichment Analysis. For this 
purpose, we utilized the PANTHER tool with Fisher exact test and false discovery rate.  
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The previously selected DNA repair genes (Fig. 14), were re-analyzed to show 
the difference between genes regulated by AR-A and siNFATc1 (Fig. 26). These 
results demonstrate a clear regulation of important genes such as BRCA1, 
RAD51 or genes of the Fanconi Anemia pathway. Thus, we detected genes 
commonly regulated by AR-A and NFATc1 which are crucial for homologous 
recombination. This led to the assumption that NFATc1 is a crucial regulator of 








Figure 26: Selected genes involved in 
DNA repair are also regulated by 
siNFATc1. Log2 fold changes of 
selected genes involved in DNA repair, 
obtained of mRNA-seq of L3.6pl upon 
AR-A treatment and mRNA-seq of NKCII 
upon NFATc1 knockdown. Bold marked 
genes are significantly downregulated 
under AR-A treatment, displaying a 
strong regulation of DNA repair genes 
also under siNFATc1. 
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3.6.1. NFATc1 regulates DNA damage and sensitize cells to 
cisplatin treatment 
 
To further focus on the transition into in vivo experiments we continued our 
approach in KPCbl6 cells which can be orthotopically transplanted into 
immunocompetent mice. Consequently, we performed knockdown of NFATc1 in 
KPCbl6 cells to evaluate the effect on DNA damage response. Here, we could 
detect a clear induction of DNA damage after knockdown of NFATc1 (Fig. 27A). 
Interestingly, knockdown of NFATc1 leads to greater DNA damage than GSK3β 
inhibition. Thus, the strength of DNA damage with the combination of cisplatin 


































































Figure 27: Loss of NFATc1 leads to increased DNA damage under cisplatin.
A) KPCbl6 cells were treated with siNFATc1 for 6 h before combined with 1µM 
cisplatin for 24 h. The DNA damage level was determined via γH2AX, showing a 
clear induction of DNA damage under siNFATc1 and a beneficial effect, when 
combining both. B) AR-A treatment (10µM) was combined with 1µM cisplatin for 24 
hours, showing the already observed effect in DNA damage and additionally a 
downregulation of NFATc1 by AR-A. β-actin serves as loading control. 
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Following the same approach as for GSK3β, we performed an overexpression of 
NFATc1 in KPCbl6 cells and combined it with cisplatin treatment for 24 hours 
(Fig. 28). Similarly, we observed decreased basal levels of DNA damage by 
NFATc1 overexpression. In addition, NFATc1 overexpression was able to reduce 
the induced damage under cisplatin. Thus, high levels of GSK3β (Fig. 24) and 













Figure 28: Overexpression of NFATc1 
led to reduced levels of DNA damage. 
Transfection of HA-tagged constitutive 
active NFATc1 (NFATc1 c.a.) in KPCbl6 
cells for 24 hours followed by the 
combination with 1µM of cisplatin for 24 
hours. Transfection effectivity was 
controlled via HA tag. DNA damage levels 
were reduced by overexpression of 
NFATc1 and can reduce effect of cisplatin 
on DNA damage level. β-actin servers as 
loading control. 
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3.6.2. CRISPR/Cas9 mediated knockout of NFATc1 resulted in 
increased sensitivity to cisplatin 
 
Following the studies investigating a temporary reduction of NFATc1 levels, we 
used the CRISPR/Cas9 technology to create NFATc1 knockout (k.o.) cell lines. 
After confirmation of the knockout, we performed cisplatin treatment for 24 and 
48 hours. The NFATc1 k.o. cells show a strong increase of DNA damage, 
especially after 48 hours of treatment (Fig. 29).  
 
Consequently, we tested the NFATc1 k.o. cells in comparison to control on their 
sensitivity towards cisplatin via MTT assay. The results show a significantly 
higher response of the NFATc1 k.o. cells (Fig. 30A). Importantly, this effect could 
be observed in all three clones. Additionally, we tested the cisplatin response in 
KNPC (containing constitutively active NFATc1) cells. Thus, KNPC cells serve as 
an additional overexpression model of NFATc1 to verify the influence of NFATc1 
on the observed cisplatin response. These show a reduced response to cisplatin, 












































































Figure 29: KPCbl6 CRISPR/Cas9 NFATc1 knockout cells showed
induction of DNA-damage under cisplatin. KPCbl6 control and NFATc1 
knockout clones were treated with 1µM cisplatin for 24 or 48 hours. Numbers 
indicate independent cell lines generated from single cell clones. NFATc1 
knockout clones show a stronger response on DNA damage level towards 
cisplatin treatment. β-actin serves as loading control. 
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To evaluate whether NFATc1 k.o. is sufficient to mimic the effects of AR-A 
inhibition, we compared them with control cells and treated with AR-A, cisplatin, 
and the combination. As we already observed via MTT assay a strong response 
in the NFATc1 k.o. upon cisplatin treatment (Fig. 30), we performed a different 
method to confirm our results on the proliferation via BrdU assay. The 
combination treatment induced a strong decrease in cell viability in KPCbl6 
control cells by BrdU assay (Fig. 31A).  
B A 
Figure 30: NFATc1 loss leads to higher sensitivity to cisplatin and Olaparib but is not 
influenced by GSK3β inhibition. A) BrdU assay was performed in KPCbl6 control cells and 
NFATc1 knockout cells, treated for 48 hours, showing that AR-A and cisplatin is beneficial in 
control cells but not in NFATc1 knockout. B) MTT assay of KPCbl6 control and NFATc1 k.o. 
cells were treated for 72 hours with increasing concentrations of Olaparib. NFATc1 k.o. cells 
are more sensitive to Olaparib treatment. Mean ±SD, n=3 (biological replicates), unpaired 
student t-test, ** p≤ 0.01, *** p≤ 0.001. 
B A 
Figure 31: NFATc1-dependent sensitivity to cisplatin on cell viability. A) 
KPCbl6 cell (control vs NFATc1 k.o.) were treated with increasing concentration 
of cisplatin for 72 h, whereby NFATc1 k.o. cells displayed a significantly higher 
sensitivity. B) KPCbl6 cell and KNPC (constitutively active NFATc1) cells were 
treated with cisplatin for 72h. KNPC are slightly more resistant towards cisplatin 
treatment then KPCbl6 cells, but not significantly. Mean ±SD, n=3 (biological 
replicates with 5 technical replicates), unpaired student t-test, *** p≤ 0.001. 
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However, the NFATc1 k.o. cells did not show an additive effect when treated with 
cisplatin and AR-A. This leads to the assumption that the AR-A-driven cisplatin 
sensitivity is induced by NFATc1 as the loss of NFATc1 prohibits an effect of AR-
A on the response to cisplatin.  
Based on the previous observation that AR-A caused an enhanced response to 
Olaparib, we tested Olaparib in KPCbl6 NFATc1 knockout and control cells (Fig. 
31B). The loss of NFATc1 led to a significantly stronger decrease in cell viability 
compared to the control, confirming our assumption. To confirm the effect of 
NFATc1 on BRCA expression, we further performed a ChIP assay to test the 
binding capacity of NFATc1 on the TSS (Transcription Start Side) of BRCA1 and 
BRCA2 (Fig. 32). Hereby, we detected a clear difference between NFATc1-
bound TSS of BRCA1 and BRCA2, as BRCA1 was bound more by NFATc1. This 
result is in line, with our transcription analysis, showing a stronger decrease of 




Figure 32 ChIP assay for NFATc1 confirmed binding of NFATc1 on BRCA1 and 
BRCA2 TSS. ChIP assay was performed in KPCbl6 cells, treated for 24 hours with 10 µM 
AR-A or 1µM cisplatin. NFATc1 binds to the promoter and its binding is especially 
increased after cisplatin treatment. n=3 (technical replicates), Mean ±SD, unpaired student 
t-test, * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001. 
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3.6.3. NFATc1 loss impairs repair of cisplatin induced damage 
 
To further test the effect of AR-A and cisplatin on NFATc1 k.o. and control cells, 
we performed a recovery assay. Cells were treated for 24 hours with AR-A and 
cisplatin, using concentrations showing additive effects on DNA damage. After 
24 hours, the treatment was removed, cells washed with PBS to remove all 
remaining drug components in the media, followed by adding fresh media. Cells 
were allowed to recover for 24, 48 or 72 hours. We compared the effects on 
proliferation (Fig. 33) and cell morphology (Fig. 34).  
 
 
Figure 33: NFATc1 k.o. cells have a delayed recovery from cisplatin treatment. A) 
Quantification of crystal violet staining. Crystal violet was solubilized and measured 
photometric.  KPCbl6 cells were analyzed after 24 hours of treatment and 48 and 72 
hours without treatment. KPCbl6 control cells show a slower recovery of cells after 
combination treatment of cisplatin and AR-A, then to the single treatment (AR-A 10µM, 
cisplatin 1µM). In comparison, KPCbl6 NFATc1 k.o. cells do not recover from cisplatin 
treatment, without an additive effect of AR-A. B) Representative crystal violet staining 
of cells after a recovery time of 72 hours without treatment. Mean +SD, n=3 (biological 
replicates with three technical replicates), unpaired student t-test – comparing the 
treatment with DMSO control for each time point separately, *** p ≤ 0.001, **** p ≤
0.0001. 
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As shown, by crystal violet staining and its quantification, we detected that 
KPCbl6 cells were able to recover from AR-A or cisplatin treatment, after treating 
them for 24 hours (Fig. 33) shown by their increasing cell density. However, when 
both treatments were compared, we noticed a clear delay of recovery. In contrast 
to that, KPCbl6 NFATc1 k.o. cells displayed a strong delay in recovering from 
cisplatin treatment, although this effect could not be altered by the combination 
with GSK3β inhibition.  
 




Figure 34: Illustration of KPCbl6 cells after treatment with GSK3β inhibitor 
and cisplatin. KPCbl6 control (A) and NFATc1 k.o. (B) cells were treated for 24 h 
(AR-A 10µM, Cisplatin 1µM, Olaparib, 10µM and in combination with AR-A) and 
then grown in normal growth media for 24, 48 or 72 hours. Representative pictures 
are displaying the differences in the ability to recover of the treatment. 
Magnification 20x).  
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Furthermore, we performed recovery assays by using Olaparib and its 
combination with AR-A treatment (Fig. 35). However, the effects were not as 
strong as observed when using cisplatin. The western blot analysis clearly 
confirmed the results we observed on cell proliferation. After 24 hours, we 
detected DNA damage in the KPCbl6 control group when treating with all single 
reagents, which was enriched in their combination with AR-A. After a recovery 
time of 72 hours, we only observed DNA damage in the conditions that received 
the combination of cisplatin or Olaparib with AR-A. In comparison, the KPCbl6 
NFATc1 k.o. cells revealed a stronger response to cisplatin treatment on DNA 
damage level, which could not be elevated by the combination with AR-A. Even 
after 72 hours of recovery, the cells were not able to decrease the level of DNA 
damage (Fig. 35). 
Figure 35: KPCbl6 NFATc1 k.o. cells were not able to repair cisplatin-induced DNA 
damage. KPCbl6 control and NFATc1 k.o. cells were treated for 24 h (AR-A 10µM, 
Cisplatin 1µM, Olaparib 10µM and in combination with AR-A) and then grown in normal 
growth media for 48 or 72 hours. Western-blot analysis showed a delay in recovery for 
control cells when treated with AR-A in combination with cisplatin or Olaparib, whereas 
NFATc1 k.o. cells were not able to recover from single cisplatin treatment. β-actin serves 
as a loading control.    
 




In order to estimate how many patients could fit the criteria of being GSK3β-
positive and NFATc1-positive, we compared our TMA data of GSK3β with 
NFATc1 (Fig. 36). Notably, out of all patients with a GSK3β immunoreactive  
score of 2 and 3, 80% were also positive for NFATc1. Based on our results, we 
hypothesized that the remaining 20% which showed no expression for NFATc1 
would probably not benefit from an additional treatment with a GSK3β inhibitor.  
Figure 36: TMA evaluation for GSK3β and NFATc1 reveals that of the GSK3β patients the 
majority is NFATc1-positive. TMA data analyzed for their immunoreactive score (IRS) revealed 
that 47 patients showed a high IRS for GSK3β. Out of these individuals, approximately 80 % are 
NFATc1 positive and might benefit of an additional GSK3β inhibition treatment.  
 
Together, we uncovered a clear regulation of DNA damage repair-related genes 
under AR-A, which causes a higher responsiveness towards cisplatin and 
Olaparib. As a potential transcription factor causing the regulation, we identified 
NFATc1 to play an important role in the regulation and further sensitizing cells for 













Pancreatic cancer remains one of the most lethal malignancies, with a 
devastating prognosis and limited therapeutic options.1 Novel insights from recent 
seminal studies significantly increased our understanding of pancreatic cancer 
biology and most importantly, identified various molecular subtypes in pancreatic 
cancer that might play a role in the clinical course and therapeutic resistance of 
patients. These very encouraging findings must now be translated into the 
development of new therapeutic approaches and molecular treatment 
strategies.18 Stratifying patients based on variant DNA damage repair 
vulnerabilities showed highly promising results in current clinical practice. This 
led to a recent FDA approval for the use of DNA damage targeting agents, like 
PARP inhibitors, in BRCA-mutated pancreatic cancer patients.164 BRCA 
mutations are not exclusively responsible for DNA damage vulnerabilities and 
many other factors are known to attenuate DNA damage response.110 However, 
this treatment option only accounts for a small portion of patients with certain 
mutations that could benefit.  
Our study uncovers a previously uncharacterized role of GSK3β in regulating the 
transcription of DNA damage-related genes. Based on our results, we suggest 
that pharmacological targeting of GSK3β may represent a novel and effective 
strategy in the treatment of pancreatic cancer, especially in patients with induced 
DNA damage. We show, that irrespective of germline or somatic mutations in 
BRCA genes, there is also the possibility to induce a BRCAness subtype at the 
transcriptional level through inactivation of GSK3β. The inhibition of GSK3β in 
pancreatic cancer cells can therefore cause an “inducible” BRCAness-like 
phenotype. As a direct consequence a higher sensitivity towards various DNA 
damage-related agents, e.g. the PARP inhibitor, Olaparib, cisplatin and irinotecan 
is achieved. Furthermore, we unraveled the mechanistic link between GSK3β 
inhibition and “BRCAness” induction and identified NFATc1 as a key 
transcriptional driver of this central pathway in DNA damage regulation. This is in 
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line with our observation, that NFTAc1 loss recapitulates the same phenotype as 
GSK3β inhibition. 
 
4.1.  GSK3β in pancreatic cancer 
GSK3β plays an important role in numerous malignancies, which is context-
specific and reported to be mainly oncogenic in the case of pancreatic cancer.33 
In order to address this characteristic we aimed to verify these reported effects in 
our system by using both human and murine pancreatic cancer cells, L3.6pl and 
KPCbl6 cells, respectively. We observed the expected cell cycle arrest and 
reduced proliferation upon GSK3β inhibition in both systems. Gene expression 
profiling following GSK3β inhibition further revealed a role for this kinase in 
transcriptional regulation of DNA damage signatures. Our studies also proposed 
that GSK3β-driven genes are mainly involved in homologous recombination and 
repair of DNA double strand breaks. These effects were observed upon 
pharmacological GSK3β inactivation or in response to its depletion. Notably, 
GSK3β has a very broad interaction profile.165 Although our study could 
demonstrate that GSK3β regulates DNA damage repair it is crucial to further 
explore these interactions to be able to pinpoint the underlying mechanism of 
GSK3β-induced BRCAness. 
 
4.1.1. Non-BRCAness mediated chemo sensitization effects of 
GSK3β inhibition 
 
GSK3β inhibition was reported to exhibit a sensitizing effect on various 
chemotherapeutic agents.79,82,83 GSK3β inhibition sensitizes PDAC cells to 
gemcitabine treatment by stabilizing TOPBP1, which is involved in the activation 
of the ATR. This will lead to the attenuation of gemcitabine-induced cell cycle 
arrest.83 We show in this study, that GSK3β inhibition also leads to decreased 
expression levels of ATR, which supports previous findings following gemcitabine 
treatment and is in line with our observation  that GSK3β inhibition causes a 
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significant arrest of pancreatic cancer cells at the G2/M cell cycle phase, as 
shown in different systems before75,87. Pharmacological inhibition of GSK3β was 
similarly reported to sensitize tumor cells to irradiation in glioblastoma.82 This 
sensitization is mediated by inhibiting the phosphorylation of 53BP1 and thus 
attenuating the process of double-strand break repair. The sensitization to 
irradiation treatment upon GSK3β inhibition remains to be tested in PDAC.   
Alongside the transcriptional regulation of BRCAness phenotype-related genes 
which we uncover in this study, we observe a moderate but reproducible 
regulation of the nucleotide excision repair pathway induced following DNA 
adduct formation precipitated by cisplatin or bulky aromatic lesions. The family of 
Fanconi Anemia (FA) proteins were observed to be downregulated following 
GSK3β inhibition. FA proteins have a distinct influence on the regulation repair of 
DNA crosslinks caused by cisplatin treatment. As the FA and HR pathway share 
a lot of regulatory proteins and thus being conected166, an relevant interplay 
between those two pathways would not be surprising in our system.  
It has been shown, that in non-small cell lung cancer (NSCLC) a co-treatment of 
GSK3 inhibition with paclitaxel is synergistic.167 Both, paclitaxel and GSK3β 
inhibition, are known to cause stabilization of microtubule and thereby causing a 
missegregation of  chromosomes.168–170 A study of Poruchynsky et al. (2015)171 
has shown that microtubules are also important in transporting DNA damage 
repair proteins. Noteworthy, we observe in our RNA-seq results a downregulation 
of microtubule based protein transport. Therefore, this mechanism could 
contribute to the GSK3β inhibition mediated toxicity by prohibiting the transport 
of remaining DNA damage repair proteins.  It still needs to be determined if 
GSK3β inhibition induces reduced trafficking of DNA damage-related proteins 
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4.1.2. Nuclear localization of GSK3β in the context of 
chemotherapy 
 
An important observation of our study is the robust nuclear accumulation of 
GSK3β in cancer cells upon treatment with cisplatin. A similar observation was 
reported upon irradiation in glioblastoma82 which could support our hypothesis of 
the relevance of GSK3β as mediator in the DNA damage response. At this point, 
it is still unclear how the change of GSK3β localization is regulated in cancer. 
One known factor with an influence on the localization of GSK3β is AXIN2, which 
binds to GSK3β and blocks the nuclear localization sequence (NLS).55 We could 
not observe a change in the expression of AXIN2 on the transcriptional level 
following GSK3β inhibition. The counterintuitive results of AXIN2 levels suggest 
that AXIN2 expression might be controlled on the protein level upon cisplatin 
treatment leading to increased GSK3β nuclear localization. However, this 
remains to be tested. Furthermore, no changes of AXIN2 imply an influence of 
other proteins contributing to the regulation of GSK3β shuttling. If AXIN2 reveals 
to be relevant in regulating the localization of GSK3β in our system one has to 
consider, that AXIN2 itself can be upregulated by inactivating mutations of the 
Ring Finger Protein 43 (RNF43).172 RNF43 is mutated in about 7% of PDAC 
patients and its inactivation can increase Wnt signaling activity.172,173 Thus, 
RNF43 deregulation might causally be involved in the observed cellular 
redistribution of GSK3β in pancreatic cancer. The mutation status is not known 
in the cells used for our study so far.  
We could not see a consistent pattern of nuclear accumulation of GSK3β in 
various PDX tumors treated with gemcitabine and nab-paclitaxel. It has to be 
tested if this effect is specific to cisplatin and is not translated to other 
chemotherapeutics. DNA damage repair processes induced by cisplatin are more 
similar to irradiation compared to gemcitabine and nab-paclitaxel. The next step 
will be a deeper analysis, tests of different treatments and a comparison of more 
tumors in order to identify possible factors that influence this process. This is 
particularly relevant, as the first GSK3β inhibitor has been approved for clinical 
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trials only recently (NCT03678883). Molecular understanding of GSK3β and its 
role in PDAC will significantly help in identifying the subgroups of patients that will 
benefit the most from such inhibitor.  
 
4.1.3. GSK3β inhibition in different subgroups of pancreatic 
cancer patients 
 
Various molecular subtypes in pancreatic cancer were recently defined with the 
squamous phenotype, which is considered as the most aggressive type. A recent 
study by Brunton et. al (2020)24 showed, that PDAC subtypes are also tightly 
connected to metabolic plasticity. The lipogenic profile is another indicator for a 
less aggressive subtypes, while a more glycolytic profile was observed in the 
squamous subtype.23 GSK3β is a major driver of glycolysis and therefore is highly 
connected to the squamous subtype. It has already been shown that metabolism 
and DNA repair are linked to each other by processes which influence, for 
example, the chromatin remodeling or synthesis of new nucleotides. Nucleotide 
synthesis is strongly associated with glycolysis, as an intermediate of pentose-
phosphate pathway is mandatory for its occurrence. In line with the observed 
downregulation of glycolytic genes upon GSK3β inhibition, we also see a 
downregulation of pathways related to nucleotide metabolism and synthesis. 
Accordingly, GSK3β inhibition has a high potential in decreasing the 
aggressiveness when used in patients belonging to more aggressive subtypes.  
Another factor is the dependence of the sensitivity towards GSK3β inhibition on 
chromatin accessibility.24 A known regulator of chromatin accessibility, ARID1A, 
is mutated in about 6% of pancreatic cancer patients.21 It its part of the SWI/SNF 
chromatin remodeling complex and influences several processes like 
transcription and DNA replication.  ARID1A is recruited to DSBs and contributes 
to the processing of RPA coating of ssDNA.174 We observe that pancreatic cancer 
cells are more sensitive to pharmacological GSK3β inhibition upon loss of 
ARID1A, probably caused by enhancing the disturbance of DNA damage repair. 
Based on these results, we suggest that patients with mutated ARID1A mutation 
 Discussion  
83 
 
may specifically benefit from GSK3β modulation. However, a detailed analysis of 
this mechanism needs to be performed.   
In summary, we identified a key novel role of GSK3β in pancreatic cancer. The 
effect can be mainly mediated by an induced “BRCAness” phenotype, but can 
also be complemented by other mechanisms. Deeper understanding of the 
molecular mechanisms underlying GSK3β effects will help in identifying the group 
of patients that will benefit the most from receiving this treatment. One of the 
major mechanisms of induced-BRCAness identified in this study is the 
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4.2. NFATc1 and pancreatic cancer 
 
As we identified NFATc1 as a mediator of GSK3β-induced BRCAness, we aim to 
further investigate the role of NFATc1 in this process. We expect tumors with a 
loss of NFATc1 to be more sensitive to cisplatin or Olaparib treatment. 
Consistently, we were able to observe an induction of sensitization towards 
different chemotherapeutics like cisplatin in vitro upon loss of NFATc1. Key result 
of this part of the study was the demonstration of these findings in the case of 
partial loss (knockdown) in addition to complete loss (knockout) of NFATc1. 
Based on these results it would be reasonable to treat with an NFATc1 inhbitor 
rather then targeting GSK3β as upstream protein to avoid massive side effects. 
However, only pan-NFAT inhibitors, as cyclosporin A (CsA) or tacrolimus, are 
availble. Unfortunately,  targeting the whole family of NFAT proteins causes 
strong side effects like neuro- and cardiotoxicity, as well as a strong 
immunosuppressive reaction.91,106 Thus, the available inhibitors yet do not offer 
an alternative to GSK3β inhibitors.  However, the development of a specific 
NFATc1 inhibitor would provide an interesting option to target NFATc1-regulated 
DNA damage response in an GSK3β independent manner.  
 
4.2.1. NFATc1 and chemotherapy 
 
NFATc1 has been shown to drive the transcription of DNA Damage Induced 
Apoptosis Suppressor (DDIAS), which is an important protein in cisplatin 
resistance in lung cancer.175 We do not see a transcriptional regulation of DDIAS 
upon GSK3β inhibition. However, it is not known if it might be regulated in 
cisplatin resistant pancreatic cancer. Thus, an upregulation of DDIAS in cisplatin 
resistant PDAC cell lines or tumors might be mediated by NFATc1 and can be 
targeted by GSK3β inhibition.  
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It was shown by Olabisi et al. (2008)176 that NFAT interacts with PARP where 
PARP regulates NFAT activity. PARP inhibition leads to reduced ADP-
ribosylation of NFAT which causes reduced NFAT-mediated cytokine 
expression.176 This effect was only shown on single targets and was not further 
elucidated on the genome-wide level. It is not yet known, if this also affects DNA 
damage response genes. Thus, the sensitization that we see when co-treating 
with PARP and GSK3β inhibitors could be accentuated by a partial effect of PARP 
inhibition on double-stranded break repair by directly affecting NFATc1 activation. 
Cisplatin influences calcium levels by inducing Ca+2 efflux from the 
mitochondria.177 Calcium is the most important regulatory mechanism of NFAT 
signaling. While this induction is mediated by mitochondria damage and 
apoptosis, 177 it may also lead to stronger NFAT induction, thereby further 
propagating the DNA damage repair response. It cannot be determined if 
NFATc1 activation is affected by the increased calcium influx, as we cannot see 
a difference in NFATc1 expression under cisplatin treatment in the orthotopic 
mouse model so far. Additionally, we failed to observe a consistent nuclear 
accumulation of NFATc1 at that point of time. It is important to note that the mice 
in this experiment were sacrificed a day after treatment and the effects of NFATc1 
could be time dependent. Further investigation of this response with a time-point 
study is necessary to address this question. 
To further validate the GSK3β-NFATc1 axis, we plan to analyze treated patient 
cohorts. Those will be evaluated on their GSK3β and NFATc1 levels and if those 
correspond with responsiveness upon chemotherapy. Thereby, we compare the 
levels after treatment as well as their basic level of expression and localization. 
We also plan to test the success of the combination of GSK3β inhibitor with 
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4.2.2. Transcriptional regulation of DNA damage repair genes by 
NFATc1 
 
The inhibition of GSK3β leads to the transcriptional regulation of BRCAness 
associated genes, but GSK3β does not act as a transcription factor itself. It is 
rather regulating other transcription factors by stabilization or degradation. In 
order to address this feature, we aimed to understand which factors are most 
important in regulating gene expression. In a first attempt, we tested ATF2, a 
protein which is known to be involved the regulation of genes contributing to DNA 
damage repair.178 Our RNA-seq showed downregulation of ATF2 gene 
signatures after GSK3β inhibition, but we could not observe a regulation of mRNA 
or protein levels after treatment. Based on the induction of DNA damage caused 
by a knockdown of ATF2, we focused more on determining proteins which might 
interact with ATF2 and be regulated by GSK3β inhibition. As ATF2 belongs to the 
group of AP-1 proteins, we were interested in potential interactors of these 
proteins, namely NFAT.179 Our analysis of NFATc1 knock-down and knock-out 
experiments showed a strong sensitization to cisplatin, Olaparib and irinotecan, 
validated by increased DNA damage levels and growth rate reduction. NFAT-
depleted cells were not responsive to GSK3β inhibition in spite of having similar 
growth rate to control cells. Based on these results, we concluded that NFAT is 
a major mediator of GSK3β- induced BRCAness (Fig. 37). This effect is specific 
to NFATc1, as the other proteins of the NFAT group are not affected by the 
knockdown or they are upregulated in the knockout. Additionally, cells with a loss 
of NFATc1 are not able to resolve cisplatin-induced DNA damage. Our aim is to 
identify the general localization pattern of NFATc1 in case of cisplatin treatment 
next to GSK3β inhibition on a molecular level. We expect that NFATc1 will gain 
occupancy in proximity to DNA-damage response genes including BRCA1/2 and 
other. This gain of occupancy is expected to be revered upon GSK3β inhibition 
further supporting our findings. It remains to be seen if NFATc1 is going to mainly 
be localized that the transcription starting sites (TSS) of these genes or is going 
to be localized at associated distal regulating elements. Characterization of these 
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regions of going to give insight what other transcription and epigenetic factors 
help NFATc1 driving the transcription of these genes.  
In summary, NFATc1 is an important regulator of GSK3β induced-BRCAness and 
it can be used be used to stratify patients as we do not expect that patients, who 
express low levels of NFAct1, will not benefit from GSK3β inhibition treatment 
(Fig. 38).  
 
 
Figure 37: GSK3β is regulating transcription of important genes that take part in HR and 
thereby contribute to the repair of DNA damage and support the survival. GSK3β is 
regulating the expression of HR proteins by influencing a major mediator NFATc1. The 
interaction partner of NFATc1 in this process remains to be identified. The impact of GSK3β in 
driving the expression of DNA damage repair genes involved in HR the cell supports the repair 
of DNA DSBs and thus the survival of the cell. 
 





Within this project, we could highlight the role of GSK3β in regulating DNA 
damage repair in pancreatic cancer. GSK3β inhibition induces a BRCAness-like 
phenotype, which precipitates higher sensitivity to cisplatin or PARP inhibition. 
Our analysis uncovered NFATc1 as key mediator of this process. Thus, a loss of 
NFATc1 leads to higher sensitivity to DNA damage inducing agents irrespective 
of GSK3β. Future studies are necessary to further understand the mechanism in 
order to translate these findings into clinical practice. This will significantly help in 
optimizing the therapy of pancreatic cancer using mechanism-based translational 
approaches. 
Figure 38: Graphical abstract showing a possible way of stratifying patients based 
on their mutations of BRCAness genes and their expression of GSK3β and 
NFATc1. Tumors with BRCAness gene mutations are susceptible for cisplatin or PARP 
inhibitor treatment. Patients, which are positive for GSK3β and NFATc1, would benefit 
of a GSK3β inhibition to induce a BRCAness phenotyp. 
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